Circulating tumor DNA analysis detects minimal residu in patients with stage II colon cancer

Science Translational Medicine

8, 346ra92

DOI: 10.1126/scitranslmed.aaf6219

Citation Report

#	Article	IF	Citations
1	Biomarkers in Oncology. , 2015, , 185-188.		0
2	Clinically Meaningful Use of Blood Tumor Markers in Oncology. BioMed Research International, 2016, 2016, 1-10.	0.9	49
3	Evaluation of Methylation Biomarkers for Detection of Circulating Tumor DNA and Application to Colorectal Cancer. Genes, 2016, 7, 125.	1.0	47
4	Reconciling evidence-based medicine and precision medicine in the era of big data: challenges and opportunities. Genome Medicine, 2016, 8, 134.	3.6	175
6	Blood Worth Bottling: Circulating Tumor DNA as a Cancer Biomarker. Cancer Research, 2016, 76, 5590-5591.	0.4	5
7	Hunting for the ultimate liquid cancer biopsy - let the TEP dance begin. Cell Communication and Signaling, 2016, 14, 24.	2.7	21
8	Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA. Science Translational Medicine, 2016, 8, 364ra155.	5.8	348
9	The cancer bloodhounds. Nature Biotechnology, 2016, 34, 1090-1094.	9.4	37
10	Circulating biomarkers to guide systemic therapy for urothelial carcinoma. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 502-509.	0.8	8
11	Individualised multiplexed circulating tumour DNA assays for monitoring of tumour presence in patients after colorectal cancer surgery. Scientific Reports, 2017, 7, 40737.	1.6	62
12	Serum and tissue markers in colorectal cancer: State of art. Critical Reviews in Oncology/Hematology, 2017, 111, 103-116.	2.0	20
13	Clinical Cancer Advances 2017: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. Journal of Clinical Oncology, 2017, 35, 1341-1367.	0.8	318
14	Determinants of metastatic competency in colorectal cancer. Molecular Oncology, 2017, 11, 97-119.	2.1	180
15	Circulating tumour cells and cell-free DNA in gastrointestinal cancer. Nature Reviews Gastroenterology and Hepatology, 2017, 14, 73-74.	8.2	49
16	Circulating tumor cells and circulating tumor DNA: What surgical oncologists need to know?. European Journal of Surgical Oncology, 2017, 43, 949-962.	0.5	38
17	Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nature Reviews Cancer, 2017, 17, 223-238.	12.8	1,786
18	Longitudinal monitoring of ctDNA EGFR mutation burden from urine correlates with patient response to EGFR TKIs: A case series. Lung Cancer, 2017, 108, 22-28.	0.9	23
19	Circulating tumor cells: clinical validity and utility. International Journal of Clinical Oncology, 2017, 22, 421-430.	1.0	170

#	Article	IF	Citations
20	CD74 - ROS1 Fusion in NSCLCÂDetected by Hybrid Captureâ€“Based Tissue Genomic Profiling and ctDNA Assays. Journal of Thoracic Oncology, 2017, 12, e19-e20.	0.5	6
21	Next-Generation Sequencing of Circulating Tumor DNA for Early Cancer Detection. Cell, 2017, 168, 571-574.	13.5	302
22	A population genetics perspective on the determinants of intra-tumor heterogeneity. Biochimica Et Biophysica Acta: Reviews on Cancer, 2017, 1867, 109-126.	3.3	37
23	Liquid Biopsies, What We Do Not Know (Yet). Cancer Cell, 2017, 31, 172-179.	7.7	395
24	Clinical prospects of liquid biopsies. Nature Biomedical Engineering, 2017, 1, .	11.6	31
25	Subgroups and prognostication in stage III colon cancer: future perspectives for adjuvant therapy. Annals of Oncology, 2017, 28, 958-968.	0.6	107
26	Bisulfite-converted duplexes for the strand-specific detection and quantification of rare mutations. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 4733-4738.	3.3	12
27	Future perspectives of circulating tumor DNA in colorectal cancer. Tumor Biology, 2017, 39, 101042831770574.	0.8	16
28	Cellâ€free <scp>DNA</scp> copy number variations in plasma from colorectal cancer patients. Molecular Oncology, 2017, 11, 1099-1111.	2.1	48
29	What We Know About Stage II and III Colon Cancer: Itâ€™s Still Not Enough. Targeted Oncology, 2017, 12, 265-275.	1.7	25
30	Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature, 2017, 545, 446-451.	13.7	1,287
31	Is Next-Generation Sequencing the way to go for Residual Disease Monitoring in Acute Lymphoblastic Leukemia?. Molecular Diagnosis and Therapy, 2017, 21, 481-492.	1.6	41
32	Is minimal residual disease a convincing tool to determine the treatment duration of immune checkpoint inhibitors?. Future Oncology, 2017, 13, 381-383.	1.1	4
33	Personalized test tracks cancer relapse. Nature, 2017, 545, 417-418.	13.7	10
34	Clinical Implications of Monitoring Circulating Tumor DNA in Patients with Colorectal Cancer. Clinical Cancer Research, 2017, 23, 5437-5445.	3.2	232
35	Precancer Atlas to Drive Precision Prevention Trials. Cancer Research, 2017, 77, 1510-1541.	0.4	116
36	Monitoring multiple myeloma by quantification of recurrent mutations in serum. Haematologica, 2017, 102, 1266-1272.	1.7	51
37	Intratumorous heterogeneity for RAS mutations in a treatment-naÃ¯ve colorectal tumour. Journal of Clinical Pathology, 2017, 70, 720-723.	1.0	2

#	Article	IF	Citations
38	Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Colon and Rectum, 2017, 11, 117-118.	0.0	5
39	Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer. Nature Reviews Cancer, 2017, 17, 79-92.	12.8	686
40	Clinical relevance of molecular diagnostics in gastrointestinal (GI) cancer: European Society of Digestive Oncology (ESDO) expert discussion and recommendations from the 17th European Society for Medical Oncology (ESMO)/World Congress on Gastrointestinal Cancer, Barcelona. European Journal of Cancer, 2017, 86, 305-317.	1.3	22
41	The potential of liquid biopsies for the early detection of cancer. Npj Precision Oncology, 2017, 1, 36.	2.3	126
42	High-Definition Medicine. Cell, 2017, 170, 828-843.	13.5	168
43	Circulating Cell-free DNA for Metastatic Cervical Cancer Detection, Genotyping, and Monitoring. Clinical Cancer Research, 2017, 23, 6856-6862.	3.2	70
44	Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling. Cancer Discovery, 2017, 7, 1394-1403.	7.7	701
45	Facile single-stranded DNA sequencing of human plasma DNA via thermostable group II intron reverse transcriptase template switching. Scientific Reports, 2017, 7, 8421.	1.6	28
46	Utilizing circulating tumour DNA in radiation oncology. Radiotherapy and Oncology, 2017, 124, 357-364.	0.3	19
47	Tumor Evolution as a Therapeutic Target. Cancer Discovery, 2017, 7, 805-817.	7.7	158
48	Circulating Tumor DNA Reveals Clinically Actionable Somatic Genome of Metastatic Bladder Cancer. Clinical Cancer Research, 2017, 23, 6487-6497.	3.2	121
49	Questions Regarding â€œ CD74-ROS1 Fusion in NSCLC Detected by Hybrid Capture-Based Tissue Genomic Profiling and ctDNA Assaysâ€• Journal of Thoracic Oncology, 2017, 12, e127-e128.	0.5	0
50	Analysis of Plasma Epsteinâ€“Barr Virus DNA to Screen for Nasopharyngeal Cancer. New England Journal of Medicine, 2017, 377, 513-522.	13.9	531
51	Predicting Relapse with Circulating Tumor DNA Analysis in Lung Cancer. Cancer Discovery, 2017, 7, 1368-1370.	7.7	17
53	Twenty-First Century Precision Medicine in Oncology: Genomic Profiling in Patients With Cancer. Mayo Clinic Proceedings, 2017, 92, 1583-1591.	1.4	23
54	Targeted therapies for renal cell carcinoma. Nature Reviews Nephrology, 2017, 13, 496-511.	4.1	185
55	Liquid Biopsy: Approaches to Dynamic Genotyping in Cancer. Oncology Research and Treatment, 2017, 40, 409-416.	0.8	30
56	Circulating tumour DNA (ctDNA) as a liquid biopsy for melanoma. Cancer Letters, 2017, 404, 62-69.	3.2	98

#	Article	IF	Citations
57	Precision wildlife medicine: applications of the humanâ€centred precision medicine revolution to species conservation. Global Change Biology, 2017, 23, 1792-1805.	4.2	32
58	Cancer Precision Medicine: From Cancer Screening to Drug Selection and Personalized Immunotherapy. Trends in Pharmacological Sciences, 2017, 38, 15-24.	4.0	70
59	Examining the impact of regular aspirin use and <scp>PIK3CA</scp> mutations on survival in stage 2 colon cancer. Internal Medicine Journal, 2017, 47, 88-98.	0.5	16
60	Cell-free DNA as a post-treatment surveillance strategy: current status. Seminars in Oncology, 2017, 44, 330-346.	0.8	20
62	Personalizing Therapy for Metastatic Prostate Cancer: The Role of Solid and Liquid Tumor Biopsies. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017, 37, 358-369.	1.8	9
63	Rapid, ultra low coverage copy number profiling of cell-free DNA as a precision oncology screening strategy. Oncotarget, 2017, 8, 89848-89866.	0.8	45
64	Mutational Landscape of cfDNA Identifies Distinct Molecular Features Associated With Therapeutic Response to First-Line Platinum-Based Doublet Chemotherapy in Patients with Advanced NSCLC. Theranostics, 2017, 7, 4753-4762.	4.6	25
65	Clinical utility of circulating tumor cells in patients with non-small-cell lung cancer. Translational Lung Cancer Research, 2017, 6, 486-498.	1.3	43
66	Clinical utility of circulating cell-free DNA in advanced colorectal cancer. PLoS ONE, 2017, 12, e0183949.	1.1	25
68	Circulating tumor DNA detection in head and neck cancer: evaluation of two different detection approaches. Oncotarget, 2017, 8, 72621-72632.	0.8	51
69	Circulating tumor cells: silent predictors of metastasis. F1000Research, 2017, 6, 1445.	0.8	37
70	Validation of a Circulating Tumor-Derived DNA Blood Test for Detection of Methylated BCAT1 and IKZF1 DNA. journal of applied laboratory medicine, The, 2017, 2, 165-175.	0.6	9
71	Is Circulating Tumor DNA (Ctdna) Use Ready For Prime Time? Applications and Challenges of Ctdna in the Era of Precision Oncology. Chemotherapy, 2017, 06, .	0.0	0
72	To Treat or Not to Treat: Adjuvant Therapy for Stage II Colon Cancer in the Era of Precision Oncology. Journal of Oncology Practice, 2017, 13, 242-244.	2.5	3
73	Adjuvant Chemotherapy for Stage II Colon Cancer: A Clinical Dilemma. Journal of Oncology Practice, 2017, 13, 233-241.	2.5	138
74	Adjuvant Chemotherapy for Stage II Colon Cancer: The Debate Goes On. Journal of Oncology Practice, 2017, 13, 245-246.	2.5	14
75	Liquid biopsies in lung cancerâ€"time to implement research technologies in routine care?. Annals of Translational Medicine, 2017, 5, 278-278.	0.7	27
76	Clinical and biological significance of circulating tumor cells, circulating tumor DNA, and exosomes as biomarkers in colorectal cancer. Oncotarget, 2017, 8, 55632-55645.	0.8	116

#	Article	IF	Citations
77	Liquid biopsy for ctDNA to revolutionize the care of patients with early stage lung cancers. Annals of Translational Medicine, 2017, 5, 479-479.	0.7	11
78	Urine test for EGFR analysis in patients with non-small cell lung cancer. Journal of Thoracic Disease, 2017, 9, S1323-S1331.	0.6	19
79	Genetic profiling of cancer with circulating tumor DNA analysis. Journal of Genetics and Genomics, 2018, 45, 79-85.	1.7	26
80	Dynamic changes of circulating tumour DNA in surgical lung cancer patients: protocol for a prospective observational study. BMJ Open, 2018, 8, e019012.	0.8	8
81	Insights from Large-Scale Cancer Genome Sequencing. Annual Review of Cancer Biology, 2018, 2, 429-444.	2.3	5
82	Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. Archives of Pathology and Laboratory Medicine, 2018, 142, 1242-1253.	1.2	120
83	Accelerating Therapeutic Development through Innovative Trial Design in Colorectal Cancer. Current Treatment Options in Oncology, 2018, 19, 11.	1.3	3
84	Liquid Biopsy in Head and Neck Cancer: Promises and Challenges. Journal of Dental Research, 2018, 97, 701-708.	2.5	92
85	Adjuvant therapy for resected colon cancer 2017, including the IDEA analysis. Expert Review of Anticancer Therapy, 2018, 18, 339-349.	1.1	6
86	Methylation in cell-free DNA for early cancer detection. Annals of Oncology, 2018, 29, 1351-1353.	0.6	22
87	Circulating tumor DNA: A promising biomarker to guide postoperative treatment and surveillance of nonâ€“small cell lung cancer. Journal of Thoracic and Cardiovascular Surgery, 2018, 155, 2628-2631.	0.4	10
88	Clinical indications for, and the future of, circulating tumor cells. Advanced Drug Delivery Reviews, 2018, 125, 143-150.	6.6	57
89	Role of circulating tumor DNA in the management of patients with colorectal cancer. Clinics and Research in Hepatology and Gastroenterology, 2018, 42, 396-402.	0.7	14
90	A pilot study of ultra-deep targeted sequencing of plasma DNA identifies driver mutations in hepatocellular carcinoma. Oncogene, 2018, 37, 3740-3752.	2.6	89
91	Extending Circulating Tumor DNA Analysis to Ultralow Abundance Mutations: Techniques and Challenges. ACS Sensors, 2018, 3, 540-560.	4.0	31
92	Optimized targeted sequencing of cell-free plasma DNA from bladder cancer patients. Scientific Reports, 2018, 8, 1917.	1.6	50
93	The value of cellâ€free DNA for molecular pathology. Journal of Pathology, 2018, 244, 616-627.	2.1	91
94	Circulating tumour cells and DNA as liquid biopsies in gastrointestinal cancer. British Journal of Surgery, 2018, 105, e110-e120.	0.1	49

#	Article	IF	Citations
95	Circulating tumour DNA analyses reveal novel resistance mechanisms to CDK inhibition in metastatic breast cancer. Annals of Oncology, 2018, 29, 535-537.	0.6	8
96	KRAS and BRAF mutations in circulating tumour DNA from locally advanced rectal cancer. Scientific Reports, 2018, 8, 1445.	1.6	55
97	Hybrid Captureâ€"Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Cancers of the Gastrointestinal Tract or Anus. Clinical Cancer Research, 2018, 24, 1881-1890.	3.2	59
98	Critical research gaps and recommendations to inform research prioritisation for more effective prevention and improved outcomes in colorectal cancer. Gut, 2018, 67, 179-193.	6.1	73
99	Circulating cell-free DNA as predictor of treatment failure after neoadjuvant chemo-radiotherapy before surgery in patients with locally advanced rectal cancer. Annals of Oncology, 2018, 29, 610-615.	0.6	51
100	Incorporating blood-based liquid biopsy information into cancer staging: time for a TNMB system?. Annals of Oncology, 2018, 29, 311-323.	0.6	74
101	Circulating tumor DNA predicts survival in patients with resected high-risk stage II/III melanoma. Annals of Oncology, 2018, 29, 490-496.	0.6	124
102	Advances in liquid biopsy approaches for early detection and monitoring of cancer. Genome Medicine, 2018, 10, 21.	3.6	85
103	The emerging clinical relevance of genomics in cancer medicine. Nature Reviews Clinical Oncology, 2018, 15, 353-365.	12.5	351
104	Colorectal cancer early methylation alterations affect the crosstalk between cell and surrounding environment, tracing a biomarker signature specific for this tumor. International Journal of Cancer, 2018, 143, 907-920.	2.3	41
105	Circulating cell-free DNA for non-invasive cancer management. Cancer Genetics, 2018, 228-229, 169-179.	0.2	71
106	JAK2 V617F mutation in plasma cell-free DNA preceding clinically overt myelofibrosis: Implications for early diagnosis. Cancer Biology and Therapy, 2018, 19, 664-668.	1.5	4
107	Enhancing the accuracy of next-generation sequencing for detecting rare and subclonal mutations. Nature Reviews Genetics, 2018, 19, 269-285.	7.7	374
108	Monitoring colorectal cancer following surgery using plasma circulating tumor DNA. Oncology Letters, 2018, 15, 4365-4375.	0.8	24
109	Circulating tumor DNA testing in advanced non-small cell lung cancer. Lung Cancer, 2018, 119, 42-47.	0.9	31
110	Liquid biopsy: another tool towards tailored therapy in colorectal cancer. Annals of Oncology, 2018, 29, 7-8.	0.6	18
111	Circulating tumor DNA as a biomarker to guide therapy in post-operative locally advanced rectal cancer: the best option?. Expert Review of Molecular Diagnostics, 2018, 18, 1-3.	1.5	13
112	Monitoring Treatment Response and Metastatic Relapse in Advanced Bladder Cancer by Liquid Biopsy Analysis. European Urology, 2018, 73, 535-540.	0.9	112

#	Article	IF	Citations
113	Incidental Detection of Maternal Neoplasia in Noninvasive Prenatal Testing. Clinical Chemistry, 2018, 64, 329-335.	1.5	79
114	New Developments in the Molecular Mechanisms of Pancreatic Tumorigenesis. Advances in Anatomic Pathology, 2018, 25, 131-142.	2.4	37
115	Clinical utility of emerging liquid biomarkers in advanced prostate cancer. Cancer Genetics, 2018, 228-229, 151-158.	0.2	11
116	Longitudinal Cell-Free DNA Analysis in Patients with Small Cell Lung Cancer Reveals Dynamic Insights into Treatment Efficacy and Disease Relapse. Journal of Thoracic Oncology, 2018, 13, 112-123.	0.5	104
117	Circulating tumour DNA, a promising biomarker for the management of colorectal cancer. Critical Reviews in Oncology/Hematology, 2018, 122, 72-82.	2.0	40
118	Liquid biopsies in gastrointestinal malignancies: when is the big day?. Expert Review of Anticancer Therapy, 2018, 18, 19-38.	1.1	26
119	Parallel Evaluation of Circulating Tumor DNA and Circulating Tumor Cells in Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2018, 17, 80-83.	1.0	40
120	Droplet-based digital PCR and next generation sequencing for monitoring circulating tumor DNA: a cancer diagnostic perspective. Expert Review of Molecular Diagnostics, 2018, 18, 7-17.	1.5	165
121	Feasibility of monitoring advanced melanoma patients using cellâ€free <scp>DNA</scp> from plasma. Pigment Cell and Melanoma Research, 2018, 31, 73-81.	1.5	25
122	Circulating tumor cells in clinical research and monitoring patients with colorectal cancer. Oncotarget, 2018, 9, 24561-24571.	0.8	43
123	Precision Medicine in Nonâ€“Small Cell Lung Cancer: Current Standards in Pathology and Biomarker Interpretation. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 708-715.	1.8	30
124	Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. Journal of Clinical Oncology, 2018, 36, 1631-1641.	0.8	668
125	Liquid Biopsy to Identify Actionable Genomic Alterations. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 978-997.	1.8	54
126	Circulating Tumor DNAâ€“Defined Minimal Residual Disease in Solid Tumors: Opportunities to Accelerate the Development of Adjuvant Therapies. Journal of Clinical Oncology, 2018, 36, 3437-3440.	0.8	47
127	The role of liquid biopsy in predicting post-operative recurrence of non-small cell lung cancer. Journal of Thoracic Disease, 2018, 10, S838-S845.	0.6	36
128	The more and the heavier may not always be an answer. Journal of Thoracic Disease, 2018, 10, S1953-S1955.	0.6	1
129	Treatment redirection from cure to palliation, then cure again?â€”a cautious, but urgent matter. Translational Lung Cancer Research, 2018, 7, S5-S8.	1.3	0
130	Immunoscoreâ€”has it scored for colon cancer precision medicine?. Annals of Translational Medicine, 2018, 6, S23-S23.	0.7	6

#	Article	IF	Citations
131	Circulating tumor DNA detection: A potential tool for colorectal cancer management (Review). Oncology Letters, 2019, 17, 1409-1416.	0.8	38
132	Circulating Cell-Free Tumor DNA in the Management of Double Primary Tumors. JCO Precision Oncology, 2018, 2, 1-6.	1.5	1
133	A Sample-to-Targeted Gene Analysis Biochip for Nanofluidic Manipulation of Solid-Phase Circulating Tumor Nucleic Acid Amplification in Liquid Biopsies. ACS Sensors, 2018, 3, 2597-2603.	4.0	44
134	Enhanced detection of circulating tumor DNA by fragment size analysis. Science Translational Medicine, 2018, 10, .	5.8	670
135	The Potential Clinical Utility of Circulating Tumor DNA in Esophageal Adenocarcinoma: From Early Detection to Therapy. Frontiers in Oncology, 2018, 8, 610.	1.3	6
136	Role of miR-214 in modulating proliferation and invasion of human colon cancer SW620 cells. Oncology Letters, 2018, 16, 7175-7179.	0.8	6
137	Myeloma MRD by deep sequencing from circulating tumor DNA does not correlate with results obtained in the bone marrow. Blood Advances, 2018, 2, 2811-2813.	2.5	69
138	Notch in Ovarian Cancer. , 2018, , 153-173.		0
139	Analysis of solid tumor mutation profiles in liquid biopsy. Cancer Medicine, 2018, 7, 5439-5447.	1.3	21
140	Utility of circulating tumor DNA in cancer diagnostics with emphasis on early detection. BMC Medicine, 2018, 16, 166.	2.3	181
141	Detection of Somatic Structural Variants Enables Quantification and Characterization of Circulating Tumor DNA in Children With Solid Tumors. JCO Precision Oncology, 2018, 2018, 1-13.	1.5	95
142	Detection of endometrial precancer by a targeted gynecologic cancer liquid biopsy. Journal of Physical Education and Sports Management, 2018, 4, a003269.	0.5	11
143	Liquid Biopsy in Gastrointestinal Cancers. Diagnostics, 2018, 8, 75.	1.3	11
144	Clinically Relevant and Minimally Invasive Tumor Surveillance of Pediatric Diffuse Midline Gliomas Using Patient-Derived Liquid Biopsy. Clinical Cancer Research, 2018, 24, 5850-5859.	3.2	118
145	Application of Cell-free DNA Analysis to Cancer Treatment. New England Journal of Medicine, 2018, 379, 1754-1765.	13.9	634
146	Circulating Cell-Free DNA and Colorectal Cancer: A Systematic Review. International Journal of Molecular Sciences, 2018, 19, 3356.	1.8	79
147	Analysis of Circulating Tumor DNA and Clinical Correlates in Patients with Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma. Clinical Cancer Research, 2018, 24, 6248-6256.	3.2	89
148	Cell-Free DNA in Oncology: Gearing up for Clinic. Annals of Laboratory Medicine, 2018, 38, 1-8.	1.2	45

#	Article	IF	Citations
149	Liquid biopsy of cancer: a multimodal diagnostic tool in clinical oncology. Therapeutic Advances in Medical Oncology, 2018, 10, 175883591879463.	1.4	317
150	Evolving Tissue and Circulating Biomarkers as Prognostic and Predictive Tools in Colorectal Cancer. Current Colorectal Cancer Reports, 2018, 14, 138-151.	1.0	0
151	Molecular Diagnostics in Clinical Oncology. Frontiers in Molecular Biosciences, 2018, 5, 76.	1.6	93
152	Circulating Tumor DNA for Early Cancer Detection. journal of applied laboratory medicine, The, 2018, 3, 300-313.	0.6	25
153	The Omics Revolution Continues: The Maturation of High-Throughput Biological Data Sources. Yearbook of Medical Informatics, 2018, 27, 211-222.	0.8	21
154	Circulating tumor DNA in patients with colorectal adenomas: assessment of detectability and genetic heterogeneity. Cell Death and Disease, 2018, 9, 894.	2.7	34
155	In vitro and clinical data analysis of Osteopontin as a prognostic indicator in colorectal cancer. Journal of Cellular and Molecular Medicine, 2018, 22, 4097-4105.	1.6	42
156	Novel SERS labels: Rational design, functional integration and biomedical applications. Coordination Chemistry Reviews, 2018, 371, 11-37.	9.5	112
157	Sequencing-based counting and size profiling of plasma Epsteinâ€“Barr virus DNA enhance population screening of nasopharyngeal carcinoma. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E5115-E5124.	3.3	114
158	Early stage NSCLC â€” challenges to implementing ctDNA-based screening and MRD detection. Nature Reviews Clinical Oncology, 2018, 15, 577-586.	12.5	281
159	Shortening adjuvant chemotherapy in stage III colon cancer: are we ready for a change?. ESMO Open, 2018, 3, e000392.	2.0	0
160	Circulating Tumor DNA Assays in Clinical Cancer Research. Journal of the National Cancer Institute, 2018, 110, 929-934.	3.0	60
161	Circulating tumour DNA for monitoring colorectal cancerâ€”a prospective cohort study to assess relationship to tissue methylation, cancer characteristics and surgical resection. Clinical Epigenetics, 2018, 10, 63.	1.8	46
162	Improving Cancer Detection and Treatment with Liquid Biopsies and ptDNA. Trends in Cancer, 2018, 4, 643-654.	3.8	6
163	Circulating tumor DNA analysis depicts subclonal architecture and genomic evolution of small cell lung cancer. Nature Communications, 2018, 9, 3114.	5.8	122
164	Prognostic Impact of Residual HPV ctDNA Detection after Chemoradiotherapy for Anal Squamous Cell Carcinoma. Clinical Cancer Research, 2018, 24, 5767-5771.	3.2	68
165	The Clinical Landscape of Circulating Tumor DNA in Gastrointestinal Malignancies. Frontiers in Oncology, 2018, 8, 263.	1.3	7
166	Automated size selection for short cell-free DNA fragments enriches for circulating tumor DNA and improves error correction during next generation sequencing. PLoS ONE, 2018, 13, e0197333.	1.1	55

#	Article	IF	Citations
167	Clinical potential of circulating tumour DNA in patients receiving anticancer immunotherapy. Nature Reviews Clinical Oncology, 2018, 15, 639-650.	12.5	152
168	The utilization of next-generation sequencing to detect somatic mutations and predict clinical prognosis of Chinese non-small cell lung cancer patients. OncoTargets and Therapy, 2018, Volume 11, 2637-2646.	1.0	8
169	Neoadjuvant chemoradiotherapy followed by surgery in patients with unresectable locally advanced colon cancer: a prospective observational study. OncoTargets and Therapy, 2018, Volume 11, 409-418.	1.0	21
170	Liquid Biopsy in Clinical Management of Breast, Lung, and Colorectal Cancer. Frontiers in Medicine, 2018, 5, 9.	1.2	96
171	Understanding Intratumor Heterogeneity and Evolution in NSCLC and Potential New Therapeutic Approach. Cancers, 2018, 10, 212.	1.7	17
173	Heterogeneity in Malignant Pleural Mesothelioma. International Journal of Molecular Sciences, 2018, 19, 1603.	1.8	36
174	Liquid Biopsy in Colorectal Cancer-Current Status and Potential Clinical Applications. Micromachines, 2018, 9, 300.	1.4	26
175	A Selfâ€Digitization Dielectrophoretic (SDâ€DEP) Chip for Highâ€Efficiency Singleâ€Cell Capture, Onâ€Demand Compartmentalization, and Downstream Nucleic Acid Analysis. Angewandte Chemie, 2018, 130, 11548-11553.	1.6	12
176	Noninvasive Biomarkers of Colorectal Cancer: Role in Diagnosis and Personalised Treatment Perspectives. Gastroenterology Research and Practice, 2018, 2018, 1-21.	0.7	60
177	Targeted Sequencing of Circulating Tumor DNA to Monitor Genetic Variants and Therapeutic Response in Metastatic Colorectal Cancer. Molecular Cancer Therapeutics, 2018, 17, 2238-2247.	1.9	31
178	Relationship between post-surgery detection of methylated circulating tumor DNA with risk of residual disease and recurrence-free survival. Journal of Cancer Research and Clinical Oncology, 2018, 144, 1741-1750.	1.2	38
179	The liquid biopsy in the management of colorectal cancer patients: Current applications and future scenarios. Cancer Treatment Reviews, 2018, 70, 1-8.	3.4	116
180	A Selfâ€Digitization Dielectrophoretic (SDâ€DEP) Chip for Highâ€Efficiency Singleâ€Cell Capture, Onâ€Demand Compartmentalization, and Downstream Nucleic Acid Analysis. Angewandte Chemie - International Edition, 2018, 57, 11378-11383.	7.2	34
181	The clinical characteristics and prognostic analysis of Chinese advanced NSCLC patients based on circulating tumor DNA sequencing. OncoTargets and Therapy, 2018, Volume 11, 337-344.	1.0	4
182	Prognostic and predictive biomarkers in nonmetastatic colorectal cancers. Future Oncology, 2018, 14, 2097-2102.	1.1	4
183	Circulating tumor DNA â€“ Current state of play and future perspectives. Pharmacological Research, 2018, 136, 35-44.	3.1	31
184	Plasma Cell-Free DNA as a Predictive Marker after Radiotherapy for Hepatocellular Carcinoma. Yonsei Medical Journal, 2018, 59, 470.	0.9	23
185	The Use of Circulating Tumor DNA for Prognosis of Gastrointestinal Cancers. Frontiers in Oncology, 2018, 8, 275.	1.3	27

#	Article	IF	Citations
187	Assessing the Impact of Circulating Tumor DNA (ctDNA) in Patients With Colorectal Cancer: Separating Fact From Fiction. Frontiers in Oncology, 2018, 8, 297.	1.3	19
188	ctDNA and CTCs in Liquid Biopsy â€“ Current Status and Where We Need to Progress. Computational and Structural Biotechnology Journal, 2018, 16, 190-195.	1.9	165
189	The Utility of Liquid Biopsy in Central Nervous System Malignancies. Current Oncology Reports, 2018, 20, 60.	1.8	29
190	Impact of Emergent Circulating Tumor DNA RAS Mutation in Panitumumab-Treated Chemoresistant Metastatic Colorectal Cancer. Clinical Cancer Research, 2018, 24, 5602-5609.	3.2	45
191	Circulating tumor DNA detectable in early- and late-stage colorectal cancer patients. Bioscience Reports, 2018, 38, .	1.1	51
192	Characterizing the Cancer Genome in Blood. Cold Spring Harbor Perspectives in Medicine, 2019, 9, a026880.	2.9	7
193	A Highly Verified Assay for KRAS Mutation Detection in Tissue and Plasma of Lung, Colorectal, and Pancreatic Cancer. Archives of Pathology and Laboratory Medicine, 2019, 143, 183-189.	1.2	6
194	Enrichment technique to allow early detection and monitor emergence of KRAS mutation in response to treatment. Scientific Reports, 2019, 9, 11346.	1.6	9
195	Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer. Science Translational Medicine, 2019, 11, .	5.8	197
196	Coâ€mutational assessment of circulating tumour DNA (ctDNA) during osimertinib treatment for T790M mutant lung cancer. Journal of Cellular and Molecular Medicine, 2019, 23, 6812-6821.	1.6	12
197	Monitoring circulating tumor DNA by analyzing personalized cancer-specific rearrangements to detect recurrence in gastric cancer. Experimental and Molecular Medicine, 2019, 51, 1-10.	3.2	33
198	Genomic profile of urine has high diagnostic sensitivity compared to cytology in nonâ€invasive urothelial bladder cancer. Cancer Science, 2019, 110, 3235-3243.	1.7	24
199	Evolving Clinical Utility of Liquid Biopsy in Gastrointestinal Cancers. Cancers, 2019, 11, 1164.	1.7	12
200	ctDNA to detect minimal residual disease in pancreatic cancer: moving into clinical trials. Annals of Oncology, 2019, 30, 1410-1413.	0.6	2
201	How liquid biopsies can change clinical practice in oncology. Annals of Oncology, 2019, 30, 1580-1590.	0.6	231
202	Adjuvant hyperthermic intraperitoneal chemotherapy in patients with locally advanced colon cancer (COLOPEC): a multicentre, open-label, randomised trial. The Lancet Gastroenterology and Hepatology, 2019, 4, 761-770.	3.7	211
203	Assessment of Molecular Relapse Detection in Early-Stage Breast Cancer. JAMA Oncology, 2019, 5, 1473.	3.4	237
204	A prospective feasibility study evaluating the role of multimodality imaging and liquid biopsy for response assessment in locally advanced rectal carcinoma. Abdominal Radiology, 2019, 44, 3641-3651.	1.0	9

#	Article	IF	Citations
205	Association of post-operative CEA with survival and oxaliplatin benefit in patients with stage II colon cancer: a post hoc analysis of the MOSAIC trial. British Journal of Cancer, 2019, 121, 312-317.	2.9	17
206	In Vivo Detection of Circulating Tumor Cells in High-Risk Non-Metastatic Prostate Cancer Patients Undergoing Radiotherapy. Cancers, 2019, 11, 933.	1.7	18
207	Liquid Biopsy by Next-Generation Sequencing: a Multimodality Test for Management of Cancer. Current Hematologic Malignancy Reports, 2019, 14, 358-367.	1.2	13
208	Detection of mutational patterns in cellâ€free DNA of colorectal cancer by custom amplicon sequencing. Molecular Oncology, 2019, 13, 1669-1683.	2.1	8
209	Dynamic Risk Profiling Using Serial Tumor Biomarkers for Personalized Outcome Prediction. Cell, 2019, 178, 699-713.e19.	13.5	138
210	Carcinoembryonic Antigen Levels and Survival in Stage III Colon Cancer:Post hocAnalysis of the MOSAIC and PETACC-8 Trials. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 1153-1161.	1.1	14
211	Contemporary Approach to the Diagnosis of Malignant Pleural Effusion. Annals of the American Thoracic Society, 2019, 16, 1099-1106.	1.5	21
212	Is the Patient Cured?. JAMA Oncology, 2019, 5, 1695.	3.4	0
213	Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer. JAMA Oncology, 2019, 5, 1710.	3.4	383
214	Toward the Early Detection of Cancer by Decoding the Epigenetic and Environmental Fingerprints of Cell-Free DNA. Cancer Cell, 2019, 36, 350-368.	7.7	204
215	The Prognostic and Therapeutic Role of Genomic Subtyping by Sequencing Tumor or Cell-Free DNA in Pulmonary Large-Cell Neuroendocrine Carcinoma. Clinical Cancer Research, 2020, 26, 892-901.	3.2	80
216	Use of circulating nucleic acids, metabolites, and proteins as clinical biomarkers for earlier prognosis and diagnosis of disease. , 2019, , 85-116.		2
217	The potential role of circulating tumor DNA (ctDNA) in the further investigation of colorectal cancer patients with nonspecific findings on standard investigations. International Journal of Cancer, 2019, 145, 540-547.	2.3	15
218	Precision medicine in colorectal surgery: coming to a hospital near you. ANZ Journal of Surgery, 2019, 89, 995-996.	0.3	0
219	Mutation Profiling of Malignant Lymphoma by Next-Generation Sequencing of Circulating Cell-Free DNA. Journal of Cancer, 2019, 10, 323-331.	1.2	32
220	Applications of liquid biopsies for cancer. Science Translational Medicine, 2019, 11, .	5.8	151
221	Targeted sequencing of circulating cell-free DNA in stage II-III resectable oesophageal squamous cell carcinoma patients. BMC Cancer, 2019, 19, 818.	1.1	16
222	Circulating Tumor DNA Sequencing Analysis of Gastroesophageal Adenocarcinoma. Clinical Cancer Research, 2019, 25, 7098-7112.	3.2	142

#	Article	IF	Citations
223	The current status of the clinical utility of liquid biopsies in cancer. Expert Review of Molecular Diagnostics, 2019, 19, 1031-1041.	1.5	27
224	Development and Application of Duplex Sequencing Strategy for Cell-Free DNAâ€“Based Longitudinal Monitoring of Stage IV Colorectal Cancer. Journal of Molecular Diagnostics, 2019, 21, 994-1009.	1.2	4
225	Emerging strategies in the initial management of locally advanced rectal cancer. Future Oncology, 2019, 15, 2955-2965.	1.1	6
226	Liquid biopsy for rectal cancer: A systematic review. Cancer Treatment Reviews, 2019, 79, 101893.	3.4	28
227	Targeted next-generation sequencing of circulating-tumor DNA for tracking minimal residual disease in localized colon cancer. Annals of Oncology, 2019, 30, 1804-1812.	0.6	174
228	An integrated multi-molecular sensor for simultaneous BRAFV600E protein and DNA single point mutation detection in circulating tumour cells. Lab on A Chip, 2019, 19, 738-748.	3.1	16
229	Implementing circulating tumor DNA analysis in a clinical laboratory: A user manual. Advances in Clinical Chemistry, 2019, 89, 131-188.	1.8	9
230	Cell-free DNA Analysis in Cancer. New England Journal of Medicine, 2019, 380, 501-502.	13.9	12
231	Refining the role of adjuvant chemotherapy in stage <scp>III</scp> colon cancer. Colorectal Disease, 2019, 21, 135-136.	0.7	3
232	An ultrasensitive test for profiling circulating tumor DNA using integrated comprehensive droplet digital detection. Lab on A Chip, 2019, 19, 993-1005.	3.1	42
233	Plasma Epsteinâ€“Barr virus DNA as an archetypal circulating tumour DNA marker. Journal of Pathology, 2019, 247, 641-649.	2.1	53
234	Bioinformatics Analysis for Circulating Cell-Free DNA in Cancer. Cancers, 2019, 11, 805.	1.7	44
235	Application of Microfluidic Chips in Separation and Analysis of Extracellular Vesicles in Liquid Biopsy for Cancer. Micromachines, 2019, 10, 390.	1.4	25
236	The use of PET/MRI for imaging rectal cancer. Abdominal Radiology, 2019, 44, 3559-3568.	1.0	19
237	Quantitative evidence for early metastatic seeding in colorectal cancer. Nature Genetics, 2019, 51, 1113-1122.	9.4	315
238	Monitoring of circulating tumor DNA and its aberrant methylation in the surveillance of surgical lung Cancer patients: protocol for a prospective observational study. BMC Cancer, 2019, 19, 579.	1.1	25
239	Comprehensive Liquid Profiling of Circulating Tumor DNA and Protein Biomarkers in Long-Term Follow-Up Patients with Hepatocellular Carcinoma. Clinical Cancer Research, 2019, 25, 5284-5294.	3.2	90
240	Comparison of the Clinical Sensitivity of the Idylla Platform and the OncoBEAM RAS CRC Assay for KRAS Mutation Detection in Liquid Biopsy Samples. Scientific Reports, 2019, 9, 8976.	1.6	34

#	Article	IF	Citations
241	Prognostic factors in patients with stage II colon cancer: Role of E-selectin gene polymorphisms. Digestive and Liver Disease, 2019, 51, 1198-1201.	0.4	1
242	Cell-Free DNA. , 2019, , 11-24.		1
243	Incorporating liquid biopsies into treatment decision-making: obstacles and possibilities. Drug Discovery Today, 2019, 24, 1715-1719.	3.2	10
244	Insights on CTC Biology and Clinical Impact Emerging from Advances in Capture Technology. Cells, 2019, 8, 553.	1.8	34
245	The road map of cancer precision medicine with the innovation of advanced cancer detection technology and personalized immunotherapy. Japanese Journal of Clinical Oncology, 2019, 49, 596-603.	0.6	10
246	Circulating Tumor DNA as a Clinical Test in Resected Pancreatic Cancer. Clinical Cancer Research, 2019, 25, 4973-4984.	3.2	118
247	Circulating Tumor Cells and Circulating Tumor DNA Detection in Potentially Resectable Metastatic Colorectal Cancer: A Prospective Ancillary Study to the Unicancer Prodige-14 Trial. Cells, 2019, 8, 516.	1.8	78
248	Advances in liquid biopsy using circulating tumor cells and circulating cell-free tumor DNA for detection and monitoring of breast cancer. Clinical and Experimental Medicine, 2019, 19, 271-279.	1.9	21
249	Circulating biomarkers for early detection and clinical management of colorectal cancer. Molecular Aspects of Medicine, 2019, 69, 107-122.	2.7	214
250	Can Circulating Tumor DNA in Early-Stage Colorectal Cancer Be More Than a Prognostic Biomarker?. JAMA Oncology, 2019, 5, 1101.	3.4	2
251	Prognostic Potential of Circulating Tumor DNA Measurement in Postoperative Surveillance of Nonmetastatic Colorectal Cancer. JAMA Oncology, 2019, 5, 1118.	3.4	152
252	Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients With Stages I to III Colorectal Cancer. JAMA Oncology, 2019, 5, 1124.	3.4	538
253	Translating IDEA to Practice and Beyond: Managing Stage II and III Colon Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, 226-235.	1.8	8
254	Integrating Biomarkers and Targeted Therapy Into Colorectal Cancer Management. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, 207-215.	1.8	17
255	Early Detection of Metastatic Relapse and Monitoring of Therapeutic Efficacy by Ultra-Deep Sequencing of Plasma Cell-Free DNA in Patients With Urothelial Bladder Carcinoma. Journal of Clinical Oncology, 2019, 37, 1547-1557.	0.8	298
256	Molecular Residual Disease and Adjuvant Trial Design in Solid Tumors. Clinical Cancer Research, 2019, 25, 6026-6034.	3.2	50
257	Diagnostic and prognostic impact of cell-free DNA in human cancers: Systematic review. Mutation Research - Reviews in Mutation Research, 2019, 781, 100-129.	2.4	28
258	Cell-free DNA diagnostics: current and emerging applications in oncology. Pharmacogenomics, 2019, 20, 357-380.	0.6	12

#	Article	IF	Citations
259	Designing circulating tumor DNA-based interventional clinical trials in oncology. Genome Medicine, 2019, 11, 22.	3.6	24
260	Circulating tumor DNA analyses predict progressive disease and indicate trastuzumab-resistant mechanism in advanced gastric cancer. EBioMedicine, 2019, 43, 261-269.	2.7	68
261	Genomic Assessment of Blood-Derived Circulating Tumor DNA in Patients With Colorectal Cancers: Correlation With Tissue Sequencing, Therapeutic Response, and Survival. JCO Precision Oncology, 2019, 3, 1-16.	1.5	30
262	Life and death of circulating cell-free DNA. Cancer Biology and Therapy, 2019, 20, 1057-1067.	1.5	327
263	The emerging role of cell-free DNA as a molecular marker for cancer management. Biomolecular Detection and Quantification, 2019, 17, 100087.	7.0	375
264	Prediction and monitoring of relapse in stage III melanoma using circulating tumor DNA. Annals of Oncology, 2019, 30, 804-814.	0.6	117
265	Clinical utility of circulating tumor DNA for colorectal cancer. Cancer Science, 2019, 110, 1148-1155.	1.7	106
266	Limited Sensitivity of Circulating Tumor DNA Detection by Droplet Digital PCR in Non-Metastatic Operable Gastric Cancer Patients. Cancers, 2019, 11, 396.	1.7	20
267	Liquid biopsy in newly diagnosed patients with locoregional (I-IIIA) non-small cell lung cancer. Expert Review of Molecular Diagnostics, 2019, 19, 419-427.	1.5	16
268	Using plasma cellâ€free DNA to monitor the chemoradiotherapy course of cervical cancer. International Journal of Cancer, 2019, 145, 2547-2557.	2.3	23
269	The interplay of circulating tumor DNA and chromatin modification, therapeutic resistance, and metastasis. Molecular Cancer, 2019, 18, 36.	7.9	48
270	The Value of Liquid Biopsies for Guiding Therapy Decisions in Non-small Cell Lung Cancer. Frontiers in Oncology, 2019, 9, 129.	1.3	61
271	Detection of Solid Tumor Molecular Residual DiseaseÂ(MRD) Using Circulating Tumor DNA (ctDNA). Molecular Diagnosis and Therapy, 2019, 23, 311-331.	1.6	123
272	Liquid biopsy and minimal residual disease â€" latest advances and implications for cure. Nature Reviews Clinical Oncology, 2019, 16, 409-424.	12.5	671
273	Liquid Biopsies in Cancer Diagnosis, Monitoring, and Prognosis. Trends in Pharmacological Sciences, 2019, 40, 172-186.	4.0	393
274	The Developing Story of Predictive Biomarkers in Colorectal Cancer. Journal of Personalized Medicine, 2019, 9, 12.	1.1	111
275	Recent advances in circulating nucleic acids in oncology. Annals of Oncology, 2019, 30, 374-384.	0.6	69
276	Early colorectal cancer: diagnosis, treatment and survivorship care. Critical Reviews in Oncology/Hematology, 2019, 136, 20-30.	2.0	117

#	Article	IF	Citations
277	Refining adjuvant therapy for non-metastatic colon cancer, new standards and perspectives. Cancer Treatment Reviews, 2019, 75, 1-11.	3.4	53
278	Genotyping of circulating cellâ€free DNA enables noninvasive tumor detection in myxoid liposarcomas. International Journal of Cancer, 2019, 145, 1148-1161.	2.3	23
279	Toward liquid biopsies in cancer treatment: application of circulating tumor DNA. Apmis, 2019, 127, 329-336.	0.9	16
280	Parallel serial assessment of somatic mutation and methylation profile from circulating tumor DNA predicts treatment response and impending disease progression in osimertinib-treated lung adenocarcinoma patients. Translational Lung Cancer Research, 2019, 8, 1016-1028.	1.3	16
281	Making sense of adjuvant chemotherapy in colorectal cancer. Journal of Gastrointestinal Oncology, 2019, 10, 1183-1192.	0.6	52
282	Circulating tumour DNA in early stage colorectal cancer: can blood tell all?. Annals of Translational Medicine, 2019, 7, S358-S358.	0.7	0
283	Novel Epigenetic Biomarkers in Pregnancy-Related Disorders and Cancers. Cells, 2019, 8, 1459.	1.8	17
284	Circulating tumour DNA (ctDNA) as a biomarker in metachronous melanoma and colorectal cancer- a case report. BMC Cancer, 2019, 19, 1109.	1.1	9
285	Expanding anaplastic lymphoma kinase therapeutic indication to early stage non-small cell lung cancer. Translational Lung Cancer Research, 2019, 8, S290-S297.	1.3	6
287	The Translational Status of Cancer Liquid Biopsies. Regenerative Engineering and Translational Medicine, 2021, 7, 312-352.	1.6	39
288	Current Utility and Future Applications of ctDNA in Colorectal Cancer. , 0, , .		0
289	Promising Colorectal Cancer Biomarkers for Precision Prevention and Therapy. Cancers, 2019, 11, 1932.	1.7	26
290	The Use of Circulating Tumor DNA to Monitor and Predict Response to Treatment in Colorectal Cancer. Frontiers in Genetics, 2019, 10, 1118.	1.1	63
291	Adjuvant Therapy for Stages II and III Colon Cancer: Risk Stratification, Treatment Duration, and Future Directions. Current Oncology, 2019, 26, 43-52.	0.9	28
292	Current and Emerging Biomarkers in Metastatic Colorectal Cancer. Current Oncology, 2019, 26, 7-15.	0.9	31
293	Cell-Free DNA in the Liquid Biopsy Context: Role and Differences Between ctDNA and CTC Marker in Cancer Management. Methods in Molecular Biology, 2019, 1909, 47-73.	0.4	19
294	From cfDNA to Sequencing: Workflows and Potentials. Methods in Molecular Biology, 2019, 1909, 119-125.	0.4	0
295	Liquid Biopsy for the Management of Patients with Colorectal Cancer. Digestion, 2019, 99, 39-45.	1.2	54

#	Article	IF	Citations
296	Detection and Surveillance of Bladder Cancer Using Urine Tumor DNA. Cancer Discovery, 2019, 9, 500-509.	7.7	143
297	Detection of Minimal Residual Disease Using ctDNA in Lung Cancer: Current Evidence and Future Directions. Journal of Thoracic Oncology, 2019, 14, 16-24.	0.5	100
298	The cornerstone of integrating circulating tumor DNA into cancer management. Biochimica Et Biophysica Acta: Reviews on Cancer, 2019, 1871, 1-11.	3.3	9
299	Circulating DNA in Cancer Diagnosis and Prognosis. , 2019, , 207-218.		0
300	RAS genes in colorectal carcinoma: pathogenesis, testing guidelines and treatment implications. Journal of Clinical Pathology, 2019, 72, 135-139.	1.0	28
301	Circulating Nucleic Acids Are Associated With Outcomes of Patients With Pancreatic Cancer. Gastroenterology, 2019, 156, 108-118.e4.	0.6	270
302	A Pipeline for ctDNA Detection Following Primary Tumor Profiling Using a Cancer-Related Gene Sequencing Panel. Methods in Molecular Biology, 2019, 1908, 229-241.	0.4	3
303	Potential of Liquid Biopsies for Breast Cancer Screening, Diagnosis, and Response to Treatment. Oncology, 2019, 96, 115-124.	0.9	11
304	Low-pass Whole-genome Sequencing of Circulating Cell-free DNA Demonstrates Dynamic Changes in Genomic Copy Number in a Squamous Lung Cancer Clinical Cohort. Clinical Cancer Research, 2019, 25, 2254-2263.	3.2	62
305	Circulating tumor DNA analysis in breast cancer: Is it ready for prime-time?. Cancer Treatment Reviews, 2019, 73, 73-83.	3.4	88
306	Cell-free DNA in cancer: current insights. Cellular Oncology (Dordrecht), 2019, 42, 13-28.	2.1	34
307	Circulating tumor DNA: clinical roles in diffuse large B cell lymphoma. Annals of Hematology, 2019, 98, 255-269.	0.8	17
308	Predictive and therapeutic biomarkers in chimeric antigen receptor Tâ€cell therapy: A clinical perspective. Journal of Cellular Physiology, 2019, 234, 5827-5841.	2.0	21
309	Plasma DNA Analysis in Prostate Cancer: Opportunities for Improving Clinical Management. Clinical Chemistry, 2019, 65, 100-107.	1.5	16
310	Genome-Wide Sequencing of Cell-Free DNA Identifies Copy-Number Alterations That Can Be Used for Monitoring Response to Immunotherapy in Cancer Patients. Molecular Cancer Therapeutics, 2019, 18, 448-458.	1.9	63
311	Circulating Tumor DNA: Clinical Monitoring and Early Detection. Annual Review of Cancer Biology, 2019, 3, 187-201.	2.3	6
312	Consensus and controversies regarding followâ€up after treatment with curative intent of nonmetastatic colorectal cancer: a synopsis of guidelines used in countries represented in the European Society of Coloproctology. Colorectal Disease, 2019, 21, 392-416.	0.7	25
313	Circulating cell-free DNA does not harbour a diagnostic benefit in cats with feline diffuse iris melanomas. Journal of Feline Medicine and Surgery, 2019, 21, 124-132.	0.6	8

#	Article	IF	Citations
314	Serial circulating tumour DNA analysis during multimodality treatment of locally advanced rectal cancer: a prospective biomarker study. Gut, 2019, 68, 663-671.	6.1	234
315	Advancing Biomarker Development Through Convergent Engagement: Summary Report of the 2nd International Danube Symposium on Biomarker Development, Molecular Imaging and Applied Diagnostics; March 14â€“16, 2018; Vienna, Austria. Molecular Imaging and Biology, 2020, 22, 47-65.	1.3	4
316	Circulating cell-free tumor DNA analysis in pediatric cancers. Molecular Aspects of Medicine, 2020, 72, 100819.	2.7	24
317	Liquid biopsy in oncology: a consensus statement of the Spanish Society of Pathology and the Spanish Society of Medical Oncology. Clinical and Translational Oncology, 2020, 22, 823-834.	1.2	29
318	Strategies for Colorectal Cancer Screening. Gastroenterology, 2020, 158, 418-432.	0.6	343
319	Circulating tumor DNA quantity is related to tumor volume and both predict survival in metastatic pancreatic ductal adenocarcinoma. International Journal of Cancer, 2020, 146, 1445-1456.	2.3	67
320	Circulating tumor DNA and their added value in molecular oncology. Clinical Chemistry and Laboratory Medicine, 2020, 58, 152-161.	1.4	10
321	Circulating cell-free long DNA fragments predict post-hepatectomy recurrence of colorectal liver metastases. European Journal of Surgical Oncology, 2020, 46, 108-114.	0.5	18
322	Technical progress in circulating tumor DNA analysis using next generation sequencing. Molecular and Cellular Probes, 2020, 49, 101480.	0.9	19
323	Targets, pitfalls and reference materials for liquid biopsy tests in cancer diagnostics. Molecular Aspects of Medicine, 2020, 72, 100828.	2.7	104
324	Circulating Tumor DNA Analysis for Detection of Minimal Residual Disease After Chemoradiotherapy for Localized Esophageal Cancer. Gastroenterology, 2020, 158, 494-505.e6.	0.6	147
325	Circulating epigenetic biomarkers for detection of recurrent colorectal cancer. Cancer, 2020, 126, 1460-1469.	2.0	33
326	Hypoxia differently modulates the release of mitochondrial and nuclear DNA. British Journal of Cancer, 2020, 122, 715-725.	2.9	14
327	IMPROVE-IT2: implementing noninvasive circulating tumor DNA analysis to optimize the operative and postoperative treatment for patients with colorectal cancer â€“ intervention trial 2. Study protocol. Acta OncolÃ³gica, 2020, 59, 336-341.	0.8	24
328	Liquid Biopsy Applications in the Clinic. Molecular Diagnosis and Therapy, 2020, 24, 125-132.	1.6	33
329	ABEMUS: platform-specific and data-informed detection of somatic SNVs in cfDNA. Bioinformatics, 2020, 36, 2665-2674.	1.8	7
330	The impact of hepatic arterial infusion pump chemotherapy on hepatic recurrences and survival in patients with resected colorectal liver metastases. Hpb, 2020, 22, 1271-1279.	0.1	8
331	Liquid Biopsy for Cancer: Review and Implications for the Radiologist. Radiology, 2020, 294, 5-17.	3.6	52

#	Article	IF	Citations
332	MRI Tumor Regression Grade and Circulating Tumor DNA as Complementary Tools to Assess Response and Guide Therapy Adaptation in Rectal Cancer. Clinical Cancer Research, 2020, 26, 183-192.	3.2	79
333	Developing more sensitive genomic approaches to detect radioresponse in precision radiation oncology: From tissue DNA analysis to circulating tumor DNA. Cancer Letters, 2020, 472, 108-118.	3.2	8
334	Therapeutic Monitoring of Circulating DNA Mutations in Metastatic Cancer with Personalized Digital PCR. Journal of Molecular Diagnostics, 2020, 22, 247-261.	1.2	9
335	Biomarkers for Precision Treatment in Gastric Cancer. Visceral Medicine, 2020, 36, 364-372.	0.5	14
336	The Promise of Circulating Tumor DNA (ctDNA) in the Management of Early-Stage Colon Cancer: A Critical Review. Cancers, 2020, 12, 2808.	1.7	33
337	An Introduction to the Current Management of Colorectal Cancer in the Era of Personalized Oncology. , 2020, , 1-27.		0
338	Detection of postoperative plasma circulating tumour DNA and lack of CDX2 expression as markers of recurrence in patients with localised colon cancer. ESMO Open, 2020, 5, e000847.	2.0	21
339	Circulating Tumor DNA Testing Opens New Perspectives in Melanoma Management. Cancers, 2020, 12, 2914.	1.7	26
340	Circulating Tumor DNA as a Prognostic Biomarker in Localized Non-small Cell Lung Cancer. Frontiers in Oncology, 2020, 10, 561598.	1.3	57
341	Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2020, 31, 1291-1305.	0.6	591
342	The Role of Dynamic ctDNA Monitoring During Combination Therapies of BRAF V600E-Mutated Metastatic Colorectal Cancer: A Case Report . OncoTargets and Therapy, 2020, Volume 13, 11849-11853.	1.0	3
343	Liquid biopsy versus tumor biopsy for clinical-trial recruitment. Nature Medicine, 2020, 26, 1815-1816.	15.2	29
344	Duration of adjuvant treatment for patients with stage III colon cancer. Lancet Oncology, The, 2020, 21, 1545-1547.	5.1	1
345	A Novel Prognostic Model Incorporating Carcinoembryonic Antigen in 3-Week or Longer Postoperative Period for Stage III Colon Cancer: A Multicenter Retrospective Study. Frontiers in Oncology, 2020, 10, 566784.	1.3	5
346	Residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer: locations undetected by endoscopic biopsies in the preSANO trial. British Journal of Surgery, 2020, 107, 1791-1800.	0.1	11
347	Limited Practical Utility of Liquid Biopsy in the Treated Patients with Advanced Breast Cancer. Diagnostics, 2020, 10, 523.	1.3	2
348	New guidelines for optimal patient care with localized colon cancer: recommending what is proven, but also watching what research is bringing. Annals of Oncology, 2020, 31, 1287-1288.	0.6	3
349	Circulating Tumor DNA as a Potential Marker to Detect Minimal Residual Disease and Predict Recurrence in Pancreatic Cancer. Frontiers in Oncology, 2020, 10, 1220.	1.3	33

#	Article	IF	Citations
350	Circulating Tumor DNA in KRAS positive colorectal cancer patients as a prognostic factor â€“ a systematic review and meta-analysis. Critical Reviews in Oncology/Hematology, 2020, 154, 103065.	2.0	13
351	Patient specific circulating tumor DNA fingerprints to monitor treatment response across multiple tumors. Journal of Translational Medicine, 2020, 18, 293.	1.8	20
352	Personalized Treatment Selection and Disease Monitoring Using Circulating Tumor DNA Profiling in Real-World Cancer Patient Management. Diagnostics, 2020, 10, 550.	1.3	8
353	Genomic Analysis of Localized High-Risk Prostate Cancer Circulating Tumor Cells at the Single-Cell Level. Cells, 2020, 9, 1863.	1.8	18
354	Circulating tumor DNA as a marker of minimal residual disease following local treatment of metastases from colorectal cancer. Acta OncolÃ³gica, 2020, 59, 1424-1429.	0.8	18
355	Postoperative serum CA19-9, YKL-40, CRP and IL-6 in combination with CEA as prognostic markers for recurrence and survival in colorectal cancer. Acta OncolÃ³gica, 2020, 59, 1416-1423.	0.8	27
358	An easily adaptable validated risk score predicts cancer-specific survival in stage II colon cancer. Acta OncolÃ³gica, 2020, 59, 1503-1507.	0.8	2
359	Treatment monitoring of colorectal cancer by integrated analysis of plasma concentration and sequencing of circulating tumor DNA. Molecular Cancer, 2020, 19, 150.	7.9	8
360	Liquid Biopsy as a Tool Exploring in Real-Time Both Genomic Perturbation and Resistance to EGFR Antagonists in Colorectal Cancer. Frontiers in Oncology, 2020, 10, 581130.	1.3	7
361	Integration of Online Omics-Data Resources for Cancer Research. Frontiers in Genetics, 2020, 11, 578345.	1.1	50
362	Development of circulating tumour DNA analysis for gastrointestinal cancers. ESMO Open, 2020, 5, e000600.	2.0	20
363	The Liquid Biopsy in the Management of Colorectal Cancer: An Overview. Biomedicines, 2020, 8, 308.	1.4	44
364	Generic Protocols for the Analytical Validation of Next-Generation Sequencing-Based ctDNA Assays: A Joint Consensus Recommendation of the BloodPACâ€™s Analytical Variables Working Group. Clinical Chemistry, 2020, 66, 1156-1166.	1.5	59
365	Liquid biopsy in the clinical management of hepatocellular carcinoma. Gut, 2020, 69, 2025-2034.	6.1	77
366	Multiplex detection of ctDNA mutations in plasma of colorectal cancer patients by PCR/SERS assay. Nanotheranostics, 2020, 4, 224-232.	2.7	25
367	Comprehensive literature review of randomized clinical trials examining novel treatment advances in patients with colon cancer. Journal of Gastrointestinal Oncology, 2020, 11, 790-802.	0.6	8
368	Targeted Sequencing Analysis of Matched Cell-Free DNA and White Blood Cells: A Facile Method for Detection of Residual Disease in Gastric Cancer. Global Medical Genetics, 2020, 07, 027-029.	0.4	1
369	Circulating tumor DNA is a sensitive marker for routine monitoring of treatment response in advanced colorectal cancer. Carcinogenesis, 2020, 41, 1507-1517.	1.3	11

#	Article	IF	Citations
370	Clonal Hematopoiesis in Liquid Biopsy: From Biological Noise to Valuable Clinical Implications. Cancers, 2020, 12, 2277.	1.7	83
371	Circulating Tumour DNAs and Non-Coding RNAs as Liquid Biopsies for the Management of Colorectal Cancer Patients. Gastrointestinal Disorders, 2020, 2, 212-235.	0.4	7
372	Circulating Tumor DNA in Cancer Management: A Value Proposition. journal of applied laboratory medicine, The, 2020, 5, 1017-1026.	0.6	0
373	Direct Enhanced Detection of Multiple Circulating Tumor DNA Variants in Unprocessed Plasma by Magnetic-Assisted Bioelectrocatalytic Cycling. ACS Sensors, 2020, 5, 3217-3225.	4.0	21
374	Circulating tumor DNA guided adjuvant chemotherapy in stage II colon cancer (MEDOCC-CrEATE): study protocol for a trial within a cohort study. BMC Cancer, 2020, 20, 790.	1.1	30
375	Precision medicine for adjuvant chemotherapy of resected colorectal cancer. Annals of Gastroenterological Surgery, 2020, 4, 635-645.	1.2	5
376	A mathematical model of ctDNA shedding predicts tumor detection size. Science Advances, 2020, 6, .	4.7	105
377	Stopping targeted therapy for complete responders in advanced BRAF mutant melanoma. Scientific Reports, 2020, 10, 18878.	1.6	16
378	Cell-free nucleic acid patterns in disease prediction and monitoringâ€"hype or hope?. EPMA Journal, 2020, 11, 603-627.	3.3	58
379	Tumor DNA as a Cancer Biomarker through the Lens of Colorectal Neoplasia. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 2441-2453.	1.1	5
380	Clonal Hematopoiesis in Late-Stage Nonâ€"Small-Cell Lung Cancer and Its Impact on Targeted Panel Next-Generation Sequencing. JCO Precision Oncology, 2020, 4, 1271-1279.	1.5	19
381	Circulating Extracellular Vesicles in Gynecological Tumors: Realities and Challenges. Frontiers in Oncology, 2020, 10, 565666.	1.3	8
382	Circulating Tumour DNA to Guide Treatment of Gastrointestinal Malignancies. Visceral Medicine, 2020, 36, 388-396.	0.5	4
383	Association of Bevacizumab Plus Oxaliplatin-Based Chemotherapy With Disease-Free Survival and Overall Survival in Patients With Stage II Colon Cancer. JAMA Network Open, 2020, 3, e2020425.	2.8	11
384	Development and Clinical Validation of Discriminatory Multitarget Digital Droplet PCR Assays for the Detection of Hot Spot KRAS and NRAS Mutations in Cell-Free DNA. Journal of Molecular Diagnostics, 2020, 22, 943-956.	1.2	17
385	Utility of circulating tumor cells and DNA in the management of advanced colorectal cancer. Future Oncology, 2020, 16, 1289-1299.	1.1	7
386	Circulating tumor DNA clearance predicts prognosis across treatment regimen in a large real-world longitudinally monitored advanced non-small cell lung cancer cohort. Translational Lung Cancer Research, 2020, 9, 269-279.	1.3	64
387	Deep sequencing of circulating tumor DNA detects molecular residual disease and predicts recurrence in gastric cancer. Cell Death and Disease, 2020, 11, 346.	2.7	102

#	Article	IF	Citations
388	Hydroxymethylation and tumors: can 5-hydroxymethylation be used as a marker for tumor diagnosis and treatment?. Human Genomics, 2020, 14, 15.	1.4	29
389	â€œDecision for adjuvant treatment in stage II colon cancer based on circulating tumor DNA:The CIRCULATE-PRODIGE 70 trialâ€. Digestive and Liver Disease, 2020, 52, 730-733.	0.4	18
390	The effect of surgical trauma on circulating free DNA levels in cancer patientsâ€”implications for studies of circulating tumor DNA. Molecular Oncology, 2020, 14, 1670-1679.	2.1	89
391	The clonal evolution of metastatic colorectal cancer. Science Advances, 2020, 6, eaay9691.	4.7	41
392	Serial circulating tumour DNA analysis for locally advanced rectal cancer treated with preoperative therapy: prediction of pathological response and postoperative recurrence. British Journal of Cancer, 2020, 123, 803-810.	2.9	55
393	The value of circulation tumor DNA in predicting postoperative recurrence of colorectal cancer: a meta-analysis. International Journal of Colorectal Disease, 2020, 35, 1463-1475.	1.0	11
394	A comprehensive overview of promising biomarkers in stage II colorectal cancer. Cancer Treatment Reviews, 2020, 88, 102059.	3.4	12
395	ctDNA monitoring using patient-specific sequencing and integration of variant reads. Science Translational Medicine, 2020, 12, .	5.8	116
396	Circulating Tumor DNA as a Novel Biomarker Optimizing Chemotherapy for Colorectal Cancer. Cancers, 2020, 12, 1566.	1.7	15
397	Perioperative Circulating Tumor DNA in Colorectal Liver Metastases: Concordance with Metastatic Tissue and Predictive Value for Tumor Burden and Prognosis . Cancer Management and Research, 2020, Volume 12, 1621-1630.	0.9	20
398	Cell-free Circulating Tumor DNA Variant Allele Frequency Associates with Survival in Metastatic Cancer. Clinical Cancer Research, 2020, 26, 1924-1931.	3.2	50
399	Circulating tumor DNA and liquid biopsy in oncology. Nature Cancer, 2020, 1, 276-290.	5.7	309
400	Update on optimal treatment for metastatic colorectal cancer from the AGITG expert meeting: ESMO congress 2019. Expert Review of Anticancer Therapy, 2020, 20, 251-270.	1.1	4
401	Liquid biopsy, a paradigm shift in oncology: what interventional radiologists should know. European Radiology, 2020, 30, 4496-4503.	2.3	7
402	Perspectives of the Application of Liquid Biopsy in Colorectal Cancer. BioMed Research International, 2020, 2020, 1-13.	0.9	40
403	Redefining Colorectal Cancer by Tumor Biology. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2020, 40, 147-159.	1.8	9
404	Personalized Medicineâ€”Current and Emerging Predictive and Prognostic Biomarkers in Colorectal Cancer. Cancers, 2020, 12, 812.	1.7	30
405	Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer. Clinical Cancer Research, 2020, 26, 2556-2564.	3.2	109

#	Article	IF	Citations
406	Clonal Selection of a Novel Deleterious TP53 Somatic Mutation Discovered in ctDNA of a KIT/PDGFRA Wild-Type Gastrointestinal Stromal Tumor Resistant to Imatinib. Frontiers in Pharmacology, 2020, 11, 36.	1.6	10
407	Association between Microsatellite Instability Status and Peri-Operative Release of Circulating Tumour Cells in Colorectal Cancer. Cells, 2020, 9, 425.	1.8	12
408	Prognostic potential of liquid biopsy tracking in the posttreatment surveillance of patients with nonmetastatic nasopharyngeal carcinoma. Cancer, 2020, 126, 2163-2173.	2.0	34
409	Comparison of Somatic Mutation Profiles Between Formalin-Fixed Paraffin Embedded Tissues and Plasma Cell-Free DNA from Ovarian Cancer Patients Before and After Surgery. BioResearch Open Access, 2020, 9, 73-79.	2.6	3
410	Personalized Adjuvant Treatment of Colon Cancer. Visceral Medicine, 2020, 36, 397-406.	0.5	6
411	ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectalâ€“Anal Task Forces whitepaper. Nature Reviews Clinical Oncology, 2020, 17, 757-770.	12.5	218
412	Clinical Perspective and Translational Oncology of Liquid Biopsy. Diagnostics, 2020, 10, 443.	1.3	28
413	Cellâ€free DNA profiling in retinoblastoma patients with advanced intraocular disease: An MSKCC experience. Cancer Medicine, 2020, 9, 6093-6101.	1.3	32
414	Multimodality treatment for localized gastric cancer: state of the art and new insights. Current Opinion in Oncology, 2020, 32, 347-355.	1.1	19
416	Reliability of liquid biopsy analysis: an inter-laboratory comparison of circulating tumor DNA extraction and sequencing with different platforms. Laboratory Investigation, 2020, 100, 1475-1484.	1.7	15
417	Editorial: Adjuvant chemotherapy for gastrointestinal cancers: we can do much better. Current Opinion in Oncology, 2020, 32, 344-346.	1.1	0
418	Cell-free DNA analysis reveals POLR1D-mediated resistance to bevacizumab in colorectal cancer. Genome Medicine, 2020, 12, 20.	3.6	25
419	Refining Cancer Management Using Integrated Liquid Biopsy. Theranostics, 2020, 10, 2374-2384.	4.6	39
420	Exosomal Non Coding RNA in LIQUID Biopsies as a Promising Biomarker for Colorectal Cancer. International Journal of Molecular Sciences, 2020, 21, 1398.	1.8	67
421	Current applications and challenges of circulating tumor DNA (ctDNA) in squamous cell carcinoma of the head and neck (SCCHN). Cancer Treatment Reviews, 2020, 85, 101992.	3.4	17
422	Multiplex accurate sensitive quantitation (MASQ) with application to minimal residual disease in acute myeloid leukemia. Nucleic Acids Research, 2020, 48, e40-e40.	6.5	4
423	Enabling Precision Oncology Through Precision Diagnostics. Annual Review of Pathology: Mechanisms of Disease, 2020, 15, 97-121.	9.6	50
424	White blood cell and cell-free DNA analyses for detection of residual disease in gastric cancer. Nature Communications, 2020, 11, 525.	5.8	158

#	Article	IF	Citations
425	Circulating tumor DNA dynamics predict benefit from consolidation immunotherapy in locally advanced non-small-cell lung cancer. Nature Cancer, 2020, 1, 176-183.	5.7	201
426	Feasibility of blood testing combined with PET-CT to screen for cancer and guide intervention. Science, 2020, 369, .	6.0	351
427	Liquid Biopsies Using Circulating Tumor DNA in Non-Small Cell Lung Cancer. Thoracic Surgery Clinics, 2020, 30, 165-177.	0.4	19
428	Circulating Tumor DNA as a Prognostic Marker in Stage III Colon Cancerâ€"Reply. JAMA Oncology, 2020, 6, 932.	3.4	1
430	Patient Selection for Adjuvant Chemotherapy in High-Risk Stage II Colon Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2020, 43, 279-287.	0.6	21
431	Disease Monitoring Using Post-induction Circulating Tumor DNA Analysis Following First-Line Therapy in Patients with Metastatic Colorectal Cancer. Clinical Cancer Research, 2020, 26, 4010-4017.	3.2	22
432	Serial ctDNA Monitoring to Predict Response to Systemic Therapy in Metastatic Gastrointestinal Cancers. Clinical Cancer Research, 2020, 26, 1877-1885.	3.2	67
433	Current and future applications of liquid biopsy in nonsmall cell lung cancer from early to advanced stages. European Respiratory Review, 2020, 29, 190052.	3.0	87
434	Circulating Neuroendocrine Gene Transcripts (NETest): A Postoperative Strategy for Early Identification of the Efficacy of Radical Surgery for Pancreatic Neuroendocrine Tumors. Annals of Surgical Oncology, 2020, 27, 3928-3936.	0.7	19
435	Circulating tumor-specific DNA: a stony road to clinical utility. Biomarkers in Medicine, 2020, 14, 331-333.	0.6	0
436	The Application of Circulating Tumor DNA in the Screening, Surveillance, and Treatment Monitoring of Colorectal Cancer. Annals of Surgical Oncology, 2021, 28, 1845-1858.	0.7	5
437	Liquid biopsies: Potential and challenges. International Journal of Cancer, 2021, 148, 528-545.	2.3	146
438	Prognostic significance of postsurgery circulating tumor <scp>DNA</scp> in nonmetastatic colorectal cancer: Individual patient pooled analysis of three cohort studies. International Journal of Cancer, 2021, 148, 1014-1026.	2.3	77
439	Novel Methylated DNA Markers in the Surveillance of Colorectal Cancer Recurrence. Clinical Cancer Research, 2021, 27, 141-149.	3.2	17
440	Liquid biopsy as a perioperative biomarker of digestive tract cancers: review of the literature. Surgery Today, 2021, 51, 849-861.	0.7	1
441	Serial Circulating Tumor DNA in Predicting and Monitoring the Effect of Neoadjuvant Chemoradiotherapy in Patients with Rectal Cancer: A Prospective Multicenter Study. Clinical Cancer Research, 2021, 27, 301-310.	3.2	65
442	Detection and Diagnostic Utilization of Cellular and Cell-Free Tumor DNA. Annual Review of Pathology: Mechanisms of Disease, 2021, 16, 199-222.	9.6	16
443	Tumor-derived mutations in postoperative plasma of colorectal cancer with microsatellite instability. Translational Oncology, 2021, 14, 100945.	1.7	1

#	Article	IF	Citations
444	Liquid biopsy for esophageal cancer: Is detection of circulating cellâ€free DNA as a biomarker feasible?. Cancer Communications, 2021, 41, 3-15.	3.7	10
445	Next-Generation Liquid Biopsies: Embracing Data Science in Oncology. Trends in Cancer, 2021, 7, 283-292.	3.8	42
446	Dynamic analysis of circulating tumor <scp>DNA</scp> to predict prognosis and monitor therapeutic response in metastatic relapsed cervical cancer. International Journal of Cancer, 2021, 148, 921-931.	2.3	13
447	Application of a novel self-assembling peptide to prevent hemorrhage after EMR, a feasibility and safety study. Surgical Endoscopy and Other Interventional Techniques, 2021, 35, 3564-3571.	1.3	14
448	Circulating tumor <scp>HPV DNA</scp> complements <scp>PETâ€CT</scp> in guiding management after radiotherapy in <scp>HPV</scp>â€related squamous cell carcinoma of the head and neck. International Journal of Cancer, 2021, 148, 995-1005.	2.3	33
449	Stratification of Stage III colon cancer may identify a patient group not requiring adjuvant chemotherapy. Journal of Cancer Research and Clinical Oncology, 2021, 147, 61-71.	1.2	4
450	The prognostic value of longitudinal circulating tumor DNA profiling during osimertinib treatment. Translational Lung Cancer Research, 2021, 10, 326-339.	1.3	5
451	Preoperative detection of KRAS mutated circulating tumor DNA is an independent risk factor for recurrence in colorectal cancer. Scientific Reports, 2021, 11, 441.	1.6	13
452	Circulating DNA Quantification. , 2021, , 413-426.		0
453	ctDNA as a prognostic factor in operable colon cancer patients: a systematic review and meta-analysis. Future Oncology, 2021, 17, 349-357.	1.1	3
454	Bringing circulating tumor DNA to the clinic in Hodgkin lymphoma. Haematologica, 2020, 106, 5-6.	1.7	2
455	Cause of Death and Clinical Predictors of Survival after Curative Resection for Colon Cancer. Journal of Cancer Therapy, 2021, 12, 157-173.	0.1	0
456	Circulating Tumor DNA Predicts Pathologic and Clinical Outcomes Following Neoadjuvant Chemoradiation and Surgery for Patients With Locally Advanced Rectal Cancer. JCO Precision Oncology, 2021, 5, 123-132.	1.5	30
457	Plasma Cell-Free DNA to Differentiate Malignant from Benign Thyroid Nodules. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e2262-e2270.	1.8	6
458	Chemo-specific designs for the enumeration of circulating tumor cells: advances in liquid biopsy. Journal of Materials Chemistry B, 2021, 9, 2946-2978.	2.9	8
459	Genomic and epigenomic biomarkers in colorectal cancer: From diagnosis to therapy. Advances in Cancer Research, 2021, 151, 231-304.	1.9	8
460	DNA-Loaded Extracellular Vesicles in Liquid Biopsy: Tiny Players With Big Potential?. Frontiers in Cell and Developmental Biology, 2020, 8, 622579.	1.8	20
461	Towards Routine Implementation of Liquid Biopsies in Cancer Management: It Is Always Too Early, until Suddenly It Is Too Late. Diagnostics, 2021, 11, 103.	1.3	33

#	Article	IF	Citations
463	Circulating Biomarkers in Head and Neck Cancer. , 2021, , 123-142.		0
464	Prognostic and Predictive Values of Mismatch Repair Deficiency in Non-Metastatic Colorectal Cancer. Cancers, 2021, 13, 300.	1.7	32
465	ctDNA and Adjuvant Therapy for Colorectal Cancer: Time to Re-Invent Our Treatment Paradigm. Cancers, 2021, 13, 346.	1.7	46
466	Sensitive detection of microsatellite instability in tissues and liquid biopsies: Recent developments and updates. Computational and Structural Biotechnology Journal, 2021, 19, 4931-4940.	1.9	10
467	Survival benefit of neoadjuvant chemotherapy and surgery versus surgery first for resectable colorectal liver metastases: a cohort study. ANZ Journal of Surgery, 2021, 91, 1196-1202.	0.3	5
468	What Is Known about Theragnostic Strategies in Colorectal Cancer. Biomedicines, 2021, 9, 140.	1.4	8
469	Coupled liquid biopsy and bioinformatics for pancreatic cancer early detection and precision prognostication. Molecular Cancer, 2021, 20, 34.	7.9	42
470	Human TERT promoter mutations as a prognostic biomarker in glioma. Journal of Cancer Research and Clinical Oncology, 2021, 147, 1007-1017.	1.2	21
471	ctDNA MRD Detection and Personalized Oncogenomic Analysis in Oligometastatic Colorectal Cancer From Plasma and Urine. JCO Precision Oncology, 2021, 5, 378-388.	1.5	26
472	Circulating Tumor DNA Analyses as a Potential Marker of Recurrence and Effectiveness of Adjuvant Chemotherapy for Resected Non-Small-Cell Lung Cancer. Frontiers in Oncology, 2020, 10, 595650.	1.3	19
473	Methylation status and longâ€fragment cellâ€free DNA are prognostic biomarkers for gastric cancer. Cancer Medicine, 2021, 10, 2003-2012.	1.3	16
474	The Role of Liquid Biopsy in Hepatocellular Carcinoma Prognostication. Cancers, 2021, 13, 659.	1.7	25
475	MIPP-Seq: ultra-sensitive rapid detection and validation of low-frequency mosaic mutations. BMC Medical Genomics, 2021, 14, 47.	0.7	12
476	A Genomic-Pathologic Annotated Risk Model to Predict Recurrence in Early-Stage Lung Adenocarcinoma. JAMA Surgery, 2021, 156, e205601.	2.2	52
477	Detection of Somatic Mutations with ddPCR from Liquid Biopsy of Colorectal Cancer Patients. Genes, 2021, 12, 289.	1.0	15
478	Molecular Oncology in Management of Colorectal Cancer. Indian Journal of Surgical Oncology, 2021, 12, 169-180.	0.3	0
479	Microfluidic Chip-Based Cancer Diagnosis and Prediction of Relapse by Detecting Circulating Tumor Cells and Circulating Cancer Stem Cells. Cancers, 2021, 13, 1385.	1.7	18
480	Clinical Impact of Presurgery Circulating Tumor DNA after Total Neoadjuvant Treatment in Locally Advanced Rectal Cancer: A Biomarker Study from the GEMCAD 1402 Trial. Clinical Cancer Research, 2021, 27, 2890-2898.	3.2	44

#	Article	IF	Citations
481	Dynamic Changes of Post-Radiotherapy Plasma Epsteinâ€“Barr Virus DNA in a Randomized Trial of Adjuvant Chemotherapy Versus Observation in Nasopharyngeal Cancer. Clinical Cancer Research, 2021, 27, 2827-2836.	3.2	13
482	Experimental Models of Liquid Biopsy in Hepatocellular Carcinoma Reveal Cloneâ€Dependent Release of Circulating Tumor DNA. Hepatology Communications, 2021, 5, 1095-1105.	2.0	7
484	Clinical Utility of a Cell-Free DNA Assay in Patients With Colorectal Cancer. Frontiers in Oncology, 2021, 11, 589673.	1.3	10
485	Peritoneal Metastases From Colorectal Cancer: Defining and Addressing the Challenges. Frontiers in Oncology, 2021, 11, 650098.	1.3	41
486	Trends and Factors Associated With Receipt of Upfront Surgery for Stage II to III Rectal Adenocarcinoma in the United States, 2006 to 2016. American Journal of Clinical Oncology: Cancer Clinical Trials, 2021, 44, 187-194.	0.6	0
487	Ultrasensitive circulating tumor DNA analysis enables precision medicine: experimental workflow considerations. Expert Review of Molecular Diagnostics, 2021, 21, 299-310.	1.5	23
488	Horizons in Veterinary Precision Oncology: Fundamentals of Cancer Genomics and Applications of Liquid Biopsy for the Detection, Characterization, and Management of Cancer in Dogs. Frontiers in Veterinary Science, 2021, 8, 664718.	0.9	21
489	Dynamic cfDNA Analysis by NGS in EGFR T790M-Positive Advanced NSCLC Patients Failed to the First-Generation EGFR-TKIs. Frontiers in Oncology, 2021, 11, 643199.	1.3	7
490	A Pilot Study Analyzing the Clinical Utility of Comprehensive Genomic Profiling Using Plasma Cell-Free DNA for Solid Tumor Patients in Japan (PROFILE Study). Annals of Surgical Oncology, 2021, 28, 8497-8505.	0.7	8
491	Use of Molecular Assays and Circulating Tumor DNA in Early-Stage Colorectal Cancer: A Roundtable Discussion of the Gastrointestinal Cancer Therapy Expert Group. Oncologist, 2021, 26, 651-659.	1.9	5
492	Future Perspectives in Detecting EGFR and ALK Gene Alterations in Liquid Biopsies of Patients with NSCLC. International Journal of Molecular Sciences, 2021, 22, 3815.	1.8	6
493	Liquid Biopsy: From Discovery to Clinical Application. Cancer Discovery, 2021, 11, 858-873.	7.7	407
494	Evaluating the analytical validity of circulating tumor DNA sequencing assays for precision oncology. Nature Biotechnology, 2021, 39, 1115-1128.	9.4	126
495	Extracellular genetic materials and their application in clinical practice. Cancer Genetics, 2021, 252-253, 48-63.	0.2	2
496	Personalising care in oesophageal cancer care with liquid biopsy. British Journal of Cancer, 2021, 125, 1036-1038.	2.9	1
497	Minimal Residual Disease Detection using a Plasma-only Circulating Tumor DNA Assay in Patients with Colorectal Cancer. Clinical Cancer Research, 2021, 27, 5586-5594.	3.2	178
498	Delayed Response After Confirmed Progression (DR) and Other Unique Immunotherapy-Related Treatment Concepts in Cutaneous Squamous Cell Carcinoma. Frontiers in Oncology, 2021, 11, 656611.	1.3	4
499	Longitudinal tracking of 97 esophageal adenocarcinomas using liquid biopsy sampling. Annals of Oncology, 2021, 32, 522-532.	0.6	53

#	Article	IF	Citations
500	Integrated approaches for precision oncology in colorectal cancer: The more you know, the better. Seminars in Cancer Biology, 2022, 84, 199-213.	4.3	35
502	Tissue-specific cell-free DNA degradation quantifies circulating tumor DNA burden. Nature Communications, 2021, 12, 2229.	5.8	49
503	How to use liquid biopsies to treat patients with cancer. ESMO Open, 2021, 6, 100060.	2.0	43
504	Liquid Biopsies in Solid Cancers: Implementation in a Nordic Healthcare System. Cancers, 2021, 13, 1861.	1.7	4
505	Genetic landscape of breast cancer and mutation tracking with circulating tumor DNA in Chinese women. Aging, 2021, 13, 11860-11876.	1.4	7
506	Practices and expectations on the use of circulating tumor DNA in colorectal cancer patients: A bi-national AGEO/AIOM/GERCOR/FFCD/FRENCH survey. Clinics and Research in Hepatology and Gastroenterology, 2021, 45, 101681.	0.7	4
507	Clinical relevance of circulating tumour DNA in colorectal cancer. ANZ Journal of Surgery, 2021, 91, 774-775.	0.3	1
508	ctDNA Predicts Overall Survival in Patients With NSCLC Treated With PD-L1 Blockade or With Chemotherapy. JCO Precision Oncology, 2021, 5, 827-838.	1.5	36
509	Liquid Biopsy of Methylation Biomarkers in Cell-Free DNA. Trends in Molecular Medicine, 2021, 27, 482-500.	3.5	128
510	Clinical Implication of Liquid Biopsy in Colorectal Cancer Patients Treated with Metastasectomy. Cancers, 2021, 13, 2231.	1.7	10
511	Circulating tumor DNA dynamics and recurrence risk in patients undergoing curative intent resection of colorectal cancer liver metastases: A prospective cohort study. PLoS Medicine, 2021, 18, e1003620.	3.9	88
512	Resection Margins in Head and Neck Cancer Surgery: An Update of Residual Disease and Field Cancerization. Cancers, 2021, 13, 2635.	1.7	19
513	Postoperative circulating tumor DNA as markers of recurrence risk in stages II to III colorectal cancer. Journal of Hematology and Oncology, 2021, 14, 80.	6.9	90
514	Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy for Patients with Stage 2A Colon Cancer (COBRA). Annals of Surgical Oncology, 2021, 28, 4095-4097.	0.7	8
515	Detection of low-frequency DNA variants by targeted sequencing of the Watson and Crick strands. Nature Biotechnology, 2021, 39, 1220-1227.	9.4	40
516	The molecular profiling of solid tumors by liquid biopsy: a position paper of the AIOMâ€“SIAPEC-IAPâ€“SIBioCâ€“SICâ€“SIF Italian Scientific Societies. ESMO Open, 2021, 6, 100164.	2.0	69
517	Personalized tumor-specific DNA junctions to detect circulating tumor in patients with endometrial cancer. PLoS ONE, 2021, 16, e0252390.	1.1	5
519	Circulating Tumour DNA as a Potential Cost-Effective Biomarker to Reduce Adjuvant Chemotherapy Overtreatment in Stage II Colorectal Cancer. Pharmacoeconomics, 2021, 39, 953-964.	1.7	14

#	Article	IF	Citations
520	From Sampling to Sequencing: A Liquid Biopsy Pre-Analytic Workflow to Maximize Multi-Layer Genomic Information from a Single Tube. Cancers, 2021, 13, 3002.	1.7	15
521	HPV ctDNA detection of high-risk HPV types during chemoradiotherapy for locally advanced cervical cancer. ESMO Open, 2021, 6, 100154.	2.0	30
522	Stage dependent recurrence patterns and post-recurrence outcomes in non-metastatic colon cancer. Acta OncolÃ³gica, 2021, 60, 1106-1113.	0.8	5
523	Elevated serum carcinoembryonic antigen level after curative surgery is a prognostic biomarker of stage II-III colorectal cancer. European Journal of Surgical Oncology, 2021, 47, 2880-2887.	0.5	10
524	Clinical implementation and current advancement of blood liquid biopsy in cancer. Journal of Human Genetics, 2021, 66, 909-926.	1.1	16
525	Prognostic Value and Relation with Adjuvant Treatment Duration of ctDNA in Stage III Colon Cancer: aPost HocAnalysis of the PRODIGE-GERCOR IDEA-France Trial. Clinical Cancer Research, 2021, 27, 5638-5646.	3.2	42
526	A Serum Metabolomics Classifier Derived from Elderly Patients with Metastatic Colorectal Cancer Predicts Relapse in the Adjuvant Setting. Cancers, 2021, 13, 2762.	1.7	14
527	A Synthetic DNA Construct to Evaluate the Recovery Efficiency of Cell-Free DNA Extraction and Bisulfite Modification. Clinical Chemistry, 2021, 67, 1201-1209.	1.5	6
528	Perspectives for circulating tumor DNA in clinical management of colorectal cancer. International Journal of Clinical Oncology, 2021, 26, 1420-1430.	1.0	3
529	ctDNA to Guide Adjuvant Therapy in Localized Colorectal Cancer (CRC). Cancers, 2021, 13, 2869.	1.7	19
530	Circulating Tumor DNA as a Biomarker for Outcomes Prediction in Colorectal Cancer Patients. Current Drug Targets, 2021, 22, 1010-1020.	1.0	0
531	Enhanced specificity of clinical high-sensitivity tumor mutation profiling in cell-free DNA via paired normal sequencing using MSK-ACCESS. Nature Communications, 2021, 12, 3770.	5.8	68
532	Prognostic value of preoperative circulating tumor cells counts in patients with UICC stage I-IV colorectal cancer. PLoS ONE, 2021, 16, e0252897.	1.1	17
533	ctDNA guiding adjuvant immunotherapy in urothelial carcinoma. Nature, 2021, 595, 432-437.	13.7	293
534	Detection of KRAS mutations in circulating tumour DNA from plasma and urine of patients with colorectal cancer. European Journal of Surgical Oncology, 2021, 47, 3151-3156.	0.5	14
535	Adjuvant Therapies in Colon Cancer. , 0, , .		0
536	Cardiomyocyte-Specific Circulating Cell-Free Methylated DNA in Esophageal Cancer Patients Treated with Chemoradiation. Gastrointestinal Disorders, 2021, 3, 100-112.	0.4	2
537	Detection of Tumor Recurrence via Circulating Tumor DNA Profiling in Patients with Localized Lung Cancer: Clinical Considerations and Challenges. Cancers, 2021, 13, 3759.	1.7	14

#	Article	IF	Citations
538	Circulating HPV DNA as a Marker for Early Detection of Relapse in Patients with Cervical Cancer. Clinical Cancer Research, 2021, 27, 5869-5877.	3.2	36
539	Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA. Nature Biotechnology, 2021, 39, 1537-1547.	9.4	151
540	The Emerging Importance of Tumor Genomics in Operable Non-Small Cell Lung Cancer. Cancers, 2021, 13, 3656.	1.7	8
541	The Provocative Roles of Platelets in Liver Disease and Cancer. Frontiers in Oncology, 2021, 11, 643815.	1.3	10
542	Application of Data Science in Circulating Tumor DNA Detection: A Promising Avenue Towards Liquid Biopsy. Frontiers in Oncology, 2021, 11, 692322.	1.3	4
543	Serial Circulating Tumor DNA Detection Using a Personalized, Tumor-Informed Assay in Esophageal Adenocarcinoma Patients Following Resection. Gastroenterology, 2021, 161, 1705-1708.e2.	0.6	8
544	The Potential Use of Dynamics Changes of ctDNA and cfDNA in the Perioperative Period to Predict the Recurrence Risk in Early NSCLC. Frontiers in Oncology, 2021, 11, 671963.	1.3	13
545	Quantification of Translocation-Specific ctDNA Provides an Integrating Parameter for Early Assessment of Treatment Response and Risk Stratification in Ewing Sarcoma. Clinical Cancer Research, 2021, 27, 5922-5930.	3.2	14
546	Liquid Biopsy in Hepatocellular Carcinoma: Opportunities and Challenges for Immunotherapy. Cancers, 2021, 13, 4334.	1.7	20
547	Postoperative Circulating Tumor DNA Can Predict High Risk Patients with Colorectal Cancer Based on Next-Generation Sequencing. Cancers, 2021, 13, 4190.	1.7	3
548	Advances in colorectal cancer genomics and transcriptomics drive early detection and prevention. International Journal of Biochemistry and Cell Biology, 2021, 137, 106032.	1.2	5
549	Clinical Outcomes in Nonâ€“Small-Cell Lung Cancer Patients Treated With EGFR-Tyrosine Kinase Inhibitors and Other Targeted Therapies Based on Tumor Versus Plasma Genomic Profiling. JCO Precision Oncology, 2021, 5, 1241-1249.	1.5	11
550	Postoperative circulating tumour DNA is associated with pathologic response and recurrence-free survival after resection of colorectal cancer liver metastases. EBioMedicine, 2021, 70, 103498.	2.7	16
551	Utility of ctDNA in predicting response to neoadjuvant chemoradiotherapy and prognosis assessment in locally advanced rectal cancer: A prospective cohort study. PLoS Medicine, 2021, 18, e1003741.	3.9	60
552	Cancer evolution: Darwin and beyond. EMBO Journal, 2021, 40, e108389.	3.5	118
553	How I treat stage II colon cancer patients. ESMO Open, 2021, 6, 100184.	2.0	14
554	Hepatic Clearance of Cell-Free DNA: Possible Impact on Early Metastasis Diagnosis. Molecular Diagnosis and Therapy, 2021, 25, 677-682.	1.6	7
555	The relevance of liquid biopsy in surgical oncology: The application of perioperative circulating nucleic acid dynamics in improving patient outcomes. Journal of the Royal College of Surgeons of Edinburgh, 2021, , .	0.8	1

#	Article	IF	Citations
556	Sustainable Clinical Development of Adjuvant Chemotherapy for Colon Cancer. Annals of Gastroenterological Surgery, 2022, 6, 37-45.	1.2	9
557	Role of Circulating Tumor DNA in Gastrointestinal Cancers: Current Knowledge and Perspectives. Cancers, 2021, 13, 4743.	1.7	8
558	BESPOKE study protocol: a multicentre, prospective observational study to evaluate the impact of circulating tumour DNA guided therapy on patients with colorectal cancer. BMJ Open, 2021, 11, e047831.	0.8	19
559	ctDNA on liquid biopsy for predicting response and prognosis in locally advanced rectal cancer: A systematic review. European Journal of Surgical Oncology, 2022, 48, 218-227.	0.5	16
560	Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as a Liquid Biopsy Marker in Colorectal Cancer. Cancers, 2021, 13, 4500.	1.7	11
561	The CIRCULATE Trial: Circulating Tumor DNA Based Decision for Adjuvant Treatment in Colon Cancer Stage II Evaluation (AIO-KRK-0217). Clinical Colorectal Cancer, 2022, 21, 170-174.	1.0	17
562	Precision Medicine for Colorectal Cancer with Liquid Biopsy and Immunotherapy. Cancers, 2021, 13, 4803.	1.7	6
563	Clinical Applications of Minimal Residual Disease Assessments by Tumor-Informed and Tumor-Uninformed Circulating Tumor DNA in Colorectal Cancer. Cancers, 2021, 13, 4547.	1.7	12
564	Improvement in immune dysfunction after FOLFOX chemotherapy for Stage III colon cancer is associated with improved minimal residual disease prognostic subtype and outcome. Colorectal Disease, 2021, 23, 2879-2893.	0.7	2
565	Molecular Approach to Colorectal Carcinoma. Surgical Pathology Clinics, 2021, 14, 429-441.	0.7	4
566	A fatal affair: Circulating tumor cell relationships that shape metastasis. IScience, 2021, 24, 103073.	1.9	8
567	Oncogene Concatenated Enriched Amplicon Nanopore Sequencing for rapid, accurate, and affordable somatic mutation detection. Genome Biology, 2021, 22, 227.	3.8	13
569	Circulating tumor DNA for malignant peripheral nerve sheath tumors in neurofibromatosis type 1. Journal of Neuro-Oncology, 2021, 154, 265-274.	1.4	3
570	Circulating tumour DNA for clinicians: current and future clinical applications. Clinical Radiology, 2021, 76, 737-747.	0.5	2
571	Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer. Journal of Thoracic Oncology, 2021, 16, 1647-1662.	0.5	274
573	Innovation and Advances in Precision Medicine in Head and Neck Cancer. , 2021, , 355-373.		2
574	Biomarkers in oncology. , 2021, , 195-202.		0
575	Dynamic monitoring of circulating tumor DNA to predict prognosis and efficacy of adjuvant chemotherapy after resection of colorectal liver metastases. Theranostics, 2021, 11, 7018-7028.	4.6	37

#	Article	IF	Citations
576	Efficient detection and post-surgical monitoring of colon cancer with a multi-marker DNA methylation liquid biopsy. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	51
577	Use of Circulating Cell-Free DNA to Guide Precision Medicine in Patients with Colorectal Cancer. Annual Review of Medicine, 2021, 72, 399-413.	5.0	12
578	Clinical significance of clonal hematopoiesis in the interpretation of blood liquid biopsy. Molecular Oncology, 2020, 14, 1719-1730.	2.1	62
579	Cell-Free DNA in the Management of Colorectal Cancer. Recent Results in Cancer Research, 2020, 215, 253-261.	1.8	5
580	Computational Analysis of DNA and RNA Sequencing Data Obtained from Liquid Biopsies. Recent Results in Cancer Research, 2020, 215, 347-368.	1.8	1
581	Pathophysiology of ctDNA Release into the Circulation and Its Characteristics: What Is Important for Clinical Applications. Recent Results in Cancer Research, 2020, 215, 163-180.	1.8	26
586	Discovery of methylated circulating DNA biomarkers for comprehensive non-invasive monitoring of treatment response in metastatic colorectal cancer. Gut, 2018, 67, 1995-2005.	6.1	188
587	The Use of Serial Circulating Tumor DNA to Detect Resistance Alterations in Progressive Metastatic Breast Cancer. Clinical Cancer Research, 2021, 27, 1361-1370.	3.2	25
588	Genome-wide Copy-number Alterations in Circulating Tumor DNA as a Novel Biomarker for Patients with High-grade Serous Ovarian Cancer. Clinical Cancer Research, 2021, 27, 2549-2559.	3.2	34
589	Liquid biopsy in peritoneal fluid and plasma as a prognostic factor in advanced colorectal and appendiceal tumors after complete cytoreduction and hyperthermic intraperitoneal chemotherapy. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592098135.	1.4	10
590	Blood-Based Analysis of Circulating Cell-Free DNA and Tumor Cells for Early Cancer Detection. PLoS Medicine, 2016, 13, e1002205.	3.9	49
591	Prognostic value of circulating tumor DNA in patients with colon cancer: Systematic review. PLoS ONE, 2017, 12, e0171991.	1.1	53
592	Treatment monitoring in metastatic colorectal cancer patients by quantification and KRAS genotyping of circulating cell-free DNA. PLoS ONE, 2017, 12, e0174308.	1.1	40
593	Blood collection in cell-stabilizing tubes does not impact germline DNA quality for pediatric patients. PLoS ONE, 2017, 12, e0188835.	1.1	8
594	Personalizing Therapy for Metastatic Prostate Cancer: The Role of Solid and Liquid Tumor Biopsies. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017, 37, 358-369.	1.8	8
595	Liquid biopsy for cancer management: a revolutionary but still limited new tool for precision medicine. Advances in Laboratory Medicine / Avances En Medicina De Laboratorio, 2020, 1, .	0.1	15
596	Genomic landscapes by multiregion sequencing combined with circulation tumor DNA detection contribute to molecular diagnosis in glioblastomas. Aging, 2019, 11, 11224-11243.	1.4	6
597	Circulating tumor DNA in early response assessment and monitoring of advanced colorectal cancer treated with a multi-kinase inhibitor. Oncotarget, 2018, 9, 17756-17769.	0.8	34

#	Article	IF	Citations
598	Quantitative monitoring of circulating tumor DNA predicts response of cutaneous metastatic melanoma to anti-PD1 immunotherapy. Oncotarget, 2018, 9, 25265-25276.	0.8	46
599	Monitoring melanoma recurrence with circulating tumor DNA: a proof of concept from three case studies. Oncotarget, 2019, 10, 113-122.	0.8	23
600	Personalised surveillance after treatment for high-risk cancer. Oncotarget, 2019, 10, 694-695.	0.8	2
601	Circulating tumor DNA analysis in the era of precision oncology. Oncotarget, 2020, 11, 188-211.	0.8	54
602	Detection of circulating tumor DNA in patients of operative colorectal and gastric cancers. Oncotarget, 2020, 11, 3198-3207.	0.8	12
603	Towards a comprehensive framework for cell-free DNA analysis: lessons from TRACERx. Annals of Translational Medicine, 2017, 5, 428-428.	0.7	6
604	Future perspectives from lung cancer pre-clinical models: new treatments are coming?. Translational Lung Cancer Research, 2020, 9, 2629-2644.	1.3	3
606	Cancer Biomarker Discovery for Precision Medicine: New Progress. Current Medicinal Chemistry, 2020, 26, 7655-7671.	1.2	51
607	Liquid biopsy for pediatric diffuse midline glioma: a review of circulating tumor DNA and cerebrospinal fluid tumor DNA. Neurosurgical Focus, 2020, 48, E9.	1.0	36
608	Liquid biopsies for the diagnosis and surveillance of primary pediatric central nervous system tumors: a review for practicing neurosurgeons. Neurosurgical Focus, 2020, 48, E8.	1.0	17
609	A Targeted Gene Panel for Circulating Tumor DNA Sequencing in Neuroblastoma. Frontiers in Oncology, 2020, 10, 596191.	1.3	19
610	Significance of postoperative follow-up of patients with metastatic colorectal cancer using circulating tumor DNA. World Journal of Gastroenterology, 2019, 25, 6939-6948.	1.4	24
611	Identification of circulating tumor DNA using a targeted 545â€'gene next generation sequencing panel in patients with gastric cancer. Oncology Letters, 2020, 19, 2251-2257.	0.8	2
612	Postâ€'radiation circulating tumor DNA as a prognostic factor in locally advanced esophageal squamous cell carcinoma. Oncology Letters, 2020, 21, 68.	0.8	15
613	Precision medicine for gastrointestinal cancer: Recent progress and future perspective. World Journal of Gastrointestinal Oncology, 2019, 12, 1-20.	0.8	31
614	Early stage colon cancer: Current treatment standards, evolving paradigms, and future directions. World Journal of Gastrointestinal Oncology, 2020, 12, 808-832.	0.8	59
615	Liquid Biopsies for Molecular Biology-Based Radiotherapy. International Journal of Molecular Sciences, 2021, 22, 11267.	1.8	4
616	Circulating Tumor DNA in Stage III Colorectal Cancer, beyond Minimal Residual Disease Detection, toward Assessment of Adjuvant Therapy Efficacy and Clinical Behavior of Recurrences. Clinical Cancer Research, 2022, 28, 507-517.	3.2	104

#	Article	IF	Citations
617	Potential utility of longitudinal somatic mutation and methylation profiling for predicting molecular residual disease in postoperative nonâ€small cell lung cancer patients. Cancer Medicine, 2021, 10, 8377-8386.	1.3	7
618	Perioperative circulating tumor DNA as a potential prognostic marker for operable stage I to IIIA nonâ€“small cell lung cancer. Cancer, 2022, 128, 708-718.	2.0	39
619	Evaluation of Clinical and Pathological Factors to Predict High Risk of Recurrence in Patients with Stage II Colon Cancer. Clinical Colorectal Cancer, 2021, , .	1.0	0
620	Assessing CAR T-cell therapy response using genome-wide sequencing of cell-free DNA in patients with B-cell lymphomas. Transplantation and Cellular Therapy, 2021, 28, 30.e1-30.e1.	0.6	11
621	Tumor DNA From Tumor In Situ Fluid Reveals Mutation Landscape of Minimal Residual Disease After Glioma Surgery and Risk of Early Recurrence. Frontiers in Oncology, 2021, 11, 742037.	1.3	7
622	Biomarker for the Treatment of Colorectal Cancer. Nihon Daicho Komonbyo Gakkai Zasshi, 2018, 71, 425-434.	0.1	0
623	Circulating tumor DNA as a marker of residual tumor in colon cancer. OnkologiÄeskaÃ¢ KoloproktologiÃ¢, 2018, 8, 11-16.	0.1	0
624	Genomic Applications in Colorectal Carcinomas. , 2019, , 393-399.		1
625	Circulating Tumor DNA in Colorectal Cancerâ€"From Concept to Clinic. Oncology & Hematology Review, 2019, 15, 33.	0.2	1
626	Perspective: plasticity, the enemy of the good. Cancer Drug Resistance (Alhambra, Calif), 2019, 2, 351-355.	0.9	0
627	Lâ€™ADN tumoral circulant dans le cancer colorectal. Colon and Rectum, 2019, 13, 98-101.	0.0	0
628	Identification of specific modules and significant genes associated with colon cancer by weighted gene coâ€'expression network analysis. Molecular Medicine Reports, 2019, 20, 693-700.	1.1	20
630	Impact of circulating tumor DNA early detection and serial monitoring in the management of stage I to III colorectal cancer. Annals of Translational Medicine, 2019, 7, S315-S315.	0.7	3
633	La biopsia lÃquida en el manejo del cÃ¡ncer: una nueva herramienta revolucionaria de la medicina de precisiÃ³n, aÃºn con limitaciones. Advances in Laboratory Medicine / Avances En Medicina De Laboratorio, 2020, 1, .	0.1	0
634	Future directions and management of liquid biopsy in non-small cell lung cancer. Exploration of Targeted Anti-tumor Therapy, 2020, 1, 239-252.	0.5	3
635	THE IMPORTANCE OF CIRCULATING TUMOR DNA IN THE ASSESSMENT OF METASTATIC COLORECTAL CANCER TREATMENT EFFECTIVNE. Siberian Journal of Oncology, 2021, 20, 149-161.	0.1	0
636	Impact of Immunoscore on the Management of Stage II Colon Cancer Patients: A Physician Survey. Cancers, 2021, 13, 5467.	1.7	3
637	Updates of liquid biopsy in oral cancer and multiomics analysis. Oral Diseases, 2023, 29, 51-61.	1.5	13

#	Article	IF	Citations
638	Commercial ctDNA Assays for Minimal Residual Disease Detection of Solid Tumors. Molecular Diagnosis and Therapy, 2021, 25, 757-774.	1.6	16
639	Circulating tumor DNA is a prognostic marker of tumor recurrence in stage II and III colorectal cancer: multicentric, prospective cohort study (ALGECOLS). European Journal of Cancer, 2021, 159, 24-33.	1.3	24
641	Novel CRISPR-based sequence specific enrichment methods for target loci and single base mutations. PLoS ONE, 2020, 15, e0243781.	1.1	1
642	Assaying circulating-tumor DNA to predict recurrence of localized colon cancer. Digestive Medicine Research, 2020, 3, 112-112.	0.2	0
643	Characteristics and outcomes of participants in colorectal cancer biomarker trials versus a real-world cohort. Acta OncolÃ³gica, 2021, 60, 482-490.	0.8	1
644	The mutational landscape of spinal chordomas and their sensitive detection using circulating tumor DNA. Neuro-Oncology Advances, 2021, 3, vdaa173.	0.4	6
645	The Revolution of Liquid Biopsy and Single-Cell Sequencing in the Management of Colorectal Cancer. , 2020, , 147-172.		1
646	Labordiagnostik/Tumormarker: Was ist sinnvoll/effektiv, was wird kommen?. , 2020, , 191-207.		0
647	Longitudinal Monitoring of Plasma Circulating Tumour DNA Enables the Prediction of Early Relapse in Patients with Non-Hodgkin Lymphoma: A Case Series. Diagnostics, 2021, 11, 2055.	1.3	2
648	Circulating tumor DNA dynamics analysis in a xenograft mouse model with esophageal squamous cell carcinoma. World Journal of Gastroenterology, 2021, 27, 7134-7143.	1.4	2
649	La biopsia lÃquida en el diagnÃ³stico y monitoreo de pacientes oncolÃ³gicos: oportunidades y retos en LatinoamÃ©rica. Revista Colombiana De CancerologÃa, 2020, 24, 164-77.	0.0	1
651	Circulating tumor cells: what we know, what do we want to know about them and are they ready to be used in clinics?. American Journal of Translational Research (discontinued), 2017, 9, 2807-2823.	0.0	10
652	Promising clinical application of ctDNA in evaluating immunotherapy efficacy. American Journal of Cancer Research, 2018, 8, 1947-1956.	1.4	6
653	The diagnostic and prognostic usage of circulating tumor DNA in operable hepatocellular carcinoma. American Journal of Translational Research (discontinued), 2019, 11, 6462-6474.	0.0	14
654	The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Management of Colon Cancer. Diseases of the Colon and Rectum, 2022, 65, 148-177.	0.7	118
655	Circulating Tumor DNA as a Predictive Marker of Recurrence for Patients With Stage II-III Breast Cancer Treated With Neoadjuvant Therapy. Frontiers in Oncology, 2021, 11, 736769.	1.3	17
657	Using circulating tumor DNA for colon cancer adjuvant therapy: to be or not to be?. Clinical Cancer Research, 2021, , clincanres.3564.2021.	3.2	1
658	Current and Future Clinical Applications of ctDNA in Immuno-Oncology. Cancer Research, 2022, 82, 349-358.	0.4	57

#	Article	IF	Citations
659	Circulating Tumor DNA and Minimal Residual Disease (MRD) in Solid Tumors: Current Horizons and Future Perspectives. Frontiers in Oncology, 2021, 11, 763790.	1.3	60
660	Detecting Liquid Remnants of Solid Tumors: Circulating Tumor DNA Minimal Residual Disease. Cancer Discovery, 2021, 11, 2968-2986.	7.7	116
661	The impact of DNA testing on management of patients with colorectal cancer. Annals of Gastroenterological Surgery, 2022, 6, 17-28.	1.2	3
662	Advantages and Challenges of Using ctDNA NGS to Assess the Presence of Minimal Residual Disease (MRD) in Solid Tumors. Cancers, 2021, 13, 5698.	1.7	31
663	Perioperative ctDNA-Based Molecular Residual Disease Detection for Nonâ€“Small Cell Lung Cancer: A Prospective Multicenter Cohort Study (LUNGCA-1). Clinical Cancer Research, 2022, 28, 3308-3317.	3.2	99
664	Plasma-only ctDNA-Guided MRD Detection in Patients with CRCâ€”Letter. Clinical Cancer Research, 2021, 27, 6613-6613.	3.2	0
665	FDA-led consortium studies advance quality control of targeted next generation sequencing assays for precision oncology. Precision Cancer Medicine, 2021, 4, 32-32.	1.8	4
666	Plasma-only ctDNA-Guided MRD Detection in Patients with CRCâ€”Response. Clinical Cancer Research, 2021, 27, 6614-6615.	3.2	4
667	Liquid biopsies for colorectal cancer: a narrative review of ongoing clinical trials and the current use of this technology at a comprehensive cancer center. Journal of Gastrointestinal Oncology, 2022, 13, 438-449.	0.6	5
668	Novel omics technology driving translational research in precision oncology. Advances in Genetics, 2021, 108, 81-145.	0.8	3
669	Assessment of tumor burden and response to therapy in patients with colorectal cancer using a quantitative ctDNA test for methylated BCAT1/IKZF1. Molecular Oncology, 2022, 16, 2031-2041.	2.1	12
670	Phase II Prospective, Open-Label Randomized Controlled Trial Comparing Standard of Care Chemotherapy With and Without Sequential Cytoreductive Interventions for Patients with Oligometastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor Deoxyribose Nucleic Acid (ctDNA) Levels. Annals of Surgical Oncology, 2022, 29, 4583-4592.	0.7	4
671	Circulating Tumor DNA Minimal Residual Disease Detection of Nonâ€“Small-Cell Lung Cancer Treated With Curative Intent. Journal of Clinical Oncology, 2022, 40, 567-575.	0.8	83
672	Mutational landscape of circulating tumor DNA identifies distinct molecular features associated with therapeutic response in patients with metastatic colorectal cancer. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592110706.	1.4	2
673	Using all our genomes: Bloodâ€based liquid biopsies for the early detection of cancer. View, 2022, 3, .	2.7	21
674	Wnt/β-catenin signalling: function, biological mechanisms, and therapeutic opportunities. Signal Transduction and Targeted Therapy, 2022, 7, 3.	7.1	446
675	Sensitive Quantification of Cell-Free Tumor DNA for Early Detection of Recurrence in Colorectal Cancer. Frontiers in Genetics, 2021, 12, 811291.	1.1	2
676	Clonal Hematopoiesis and Liquid Biopsy in Gastrointestinal Cancers. Frontiers in Medicine, 2021, 8, 772166.	1.2	6

#	Article	IF	Citations
677	Circulating tumor <scp>DNA</scp> for prognosis assessment and postoperative management after curativeâ€intent resection of colorectal liver metastases. International Journal of Cancer, 2022, 150, 1537-1548.	2.3	22
678	Association of neutrophil extracellular traps with the production of circulating DNA in patients with colorectal cancer. IScience, 2022, 25, 103826.	1.9	13
679	Limitations and opportunities of technologies for the analysis of cell-free DNA in cancer diagnostics. Nature Biomedical Engineering, 2022, 6, 232-245.	11.6	56
680	Exploring the Evolving Scope of Neoadjuvant Immunotherapy in NSCLC. Cancers, 2022, 14, 741.	1.7	10
681	Monitoring and adapting cancer treatment using circulating tumor DNA kinetics: Current research, opportunities, and challenges. Science Advances, 2022, 8, eabi8618.	4.7	61
682	Liquid biopsy in gliomas: A RANO review and proposals for clinical applications. Neuro-Oncology, 2022, 24, 855-871.	0.6	38
685	Utility of Cell-Free DNA Detection in Transplant Oncology. Cancers, 2022, 14, 743.	1.7	10
686	Tumour-agnostic circulating tumour DNA analysis for improved recurrence surveillance after resection of colorectal liver metastases: A prospective cohort study. European Journal of Cancer, 2022, 163, 163-176.	1.3	33
687	cfTrack: A Method of Exome-Wide Mutation Analysis of Cell-free DNA to Simultaneously Monitor the Full Spectrum of Cancer Treatment Outcomes Including MRD, Recurrence, and Evolution. Clinical Cancer Research, 2022, 28, 1841-1853.	3.2	4
688	Circulating tumor DNA (ctDNA) in adjuvant therapy of early stage colon cancer: current status and future perspectives. Acta OncolÃ³gica, 2022, 61, 523-530.	0.8	5
689	Liquid BIOpsy for MiNimal RESidual DiSease Detection in Head and Neck Squamous Cell Carcinoma (LIONESS)â€”a personalised circulating tumour DNA analysis in head and neck squamous cell carcinoma. British Journal of Cancer, 2022, 126, 1186-1195.	2.9	32
690	Tumor enhancement ratio on preoperative abdominal contrast-enhanced CT scan for predicting recurrence risk in stage II colon cancer. Abdominal Radiology, 2022, 47, 1265-1275.	1.0	1
691	Early identification of disease progression in ALK-rearranged lung cancer using circulating tumor DNA analysis. Npj Precision Oncology, 2021, 5, 100.	2.3	21
692	Prognostic Value of Circulating Tumour DNA in Asian Patients with Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. Evidence-based Complementary and Alternative Medicine, 2022, 2022, 1-8.	0.5	1
693	The Landscape of Actionable Genomic Alterations by Next-Generation Sequencing in Tumor Tissue Versus Circulating Tumor DNA in Chinese Patients With Non-Small Cell Lung Cancer. Frontiers in Oncology, 2021, 11, 751106.	1.3	7
694	Utility of Perioperative Measurement of Cell-Free DNA and Circulating Tumor DNA in Informing the Prognosis of GI Cancers: A Systematic Review. JCO Precision Oncology, 2022, 6, e2100337.	1.5	4
695	Future perspectives of uveal melanoma blood based biomarkers. British Journal of Cancer, 2022, 126, 1511-1528.	2.9	22
696	The value proposition of integrative diagnostics for (early) detection of cancer. On behalf of the EFLM interdisciplinary Task and Finish Group â€œCNAPS/CTC for early detection of cancerâ€• Clinical Chemistry and Laboratory Medicine, 2022, 60, 821-829.	1.4	6

#	Article	IF	Citations
697	Residual ctDNA after treatment predicts early relapse in patients with early-stage non-small cell lung cancer. Annals of Oncology, 2022, 33, 500-510.	0.6	124
698	Impact of Circulating Tumor DNAâ€“Based Detection of Molecular Residual Disease on the Conduct and Design of Clinical Trials for Solid Tumors. JCO Precision Oncology, 2022, 6, e2100181.	1.5	33
699	Performance characteristics of the first Food and Drug Administration (FDA)-cleared digital droplet PCR (ddPCR) assay for BCR::ABL1 monitoring in chronic myelogenous leukemia. PLoS ONE, 2022, 17, e0265278.	1.1	10
700	Integrating circulating-free DNA (cfDNA) analysis into clinical practice: opportunities and challenges. British Journal of Cancer, 2022, 127, 592-602.	2.9	36
701	Liquid Biopsy and Artificial Intelligence as Tools to Detect Signatures of Colorectal Malignancies: A Modern Approach in Patientâ€™s Stratification. Frontiers in Oncology, 2022, 12, 856575.	1.3	13
702	Liquid biopsy: a step closer to transform diagnosis, prognosis and future of cancer treatments. Molecular Cancer, 2022, 21, 79.	7.9	219
703	Circulating tumour DNA monitoring and early treatment for relapse: views from patients with early-stage melanoma. British Journal of Cancer, 2022, 126, 1450-1456.	2.9	0
704	Massively parallel enrichment of low-frequency alleles enables duplex sequencing at low depth. Nature Biomedical Engineering, 2022, 6, 257-266.	11.6	32
705	Relationship between perioperative oncological evaluation and recurrence using circulating tumor <scp>DNA</scp> with <scp> KRAS </scp> mutation in patients with colorectal cancer. Cancer Medicine, 2022, , .	1.3	2
706	A clinicianâ€™s handbook for using ctDNA throughout the patient journey. Molecular Cancer, 2022, 21, 81.	7.9	43
707	A longitudinal cohort study of watch and wait in complete clinical responders after chemo-radiotherapy for localised rectal cancer: study protocol. BMC Cancer, 2022, 22, 222.	1.1	3
708	Prognostic value of ctDNA detection in patients with early breast cancer undergoing neoadjuvant therapy: A systematic review and meta-analysis. Cancer Treatment Reviews, 2022, 104, 102362.	3.4	33
709	Liquid biopsies to monitor and direct cancer treatment in colorectal cancer. British Journal of Cancer, 2022, 127, 394-407.	2.9	41
710	Research Progress on Postoperative Minimal/Molecular Residual Disease Detection in Lung Cancer. Chronic Diseases and Translational Medicine, 2022, 8, 83-90.	0.9	4
711	Liquid Profiling for Cancer Patient Stratification in Precision Medicineâ€”Current Status and Challenges for Successful Implementation in Standard Care. Diagnostics, 2022, 12, 748.	1.3	9
712	ctDNA as a biomarker of progression in oesophageal adenocarcinoma. ESMO Open, 2022, 7, 100452.	2.0	11
713	The potential of liquid biopsy in the management of cancer patients. Seminars in Cancer Biology, 2022, 84, 69-79.	4.3	55
714	Circulating tumor DNA dynamics and response to immunotherapy in colorectal cancer. Molecular and Clinical Oncology, 2022, 16, 100.	0.4	4

#	Article	IF	Citations
715	High postoperative carcinoembryonic antigen as an indicator of highâ€'risk stageÂII colon cancer. Oncology Letters, 2022, 23, 167.	0.8	0
716	Ecology and evolution of dormant metastasis. Trends in Cancer, 2022, 8, 570-582.	3.8	17
717	BRAF-mutated colorectal adenocarcinomas: Pathological heterogeneity and clinical implications. Critical Reviews in Oncology/Hematology, 2022, 172, 103647.	2.0	10
718	Response prediction and risk stratification of patients with rectal cancer after neoadjuvant therapy through an analysis of circulating tumour DNA. EBioMedicine, 2022, 78, 103945.	2.7	26
719	Colorectal liver metastases: state-of-the-art management and surgical approaches. Langenbeck's Archives of Surgery, 2022, 407, 1765-1778.	0.8	7
720	Circulating tumor DNA as a prognostic indicator of colorectal cancer recurrenceâ€"a systematic review and meta-analysis. International Journal of Colorectal Disease, 2022, , 1.	1.0	2
721	Electrochemical detection of ctDNA mutation in non-small cell lung cancer based on CRISPR/Cas12a system. Sensors and Actuators B: Chemical, 2022, 362, 131807.	4.0	23
722	Liquid biopsies for residual disease and recurrence. Med, 2021, 2, 1292-1313.	2.2	15
723	Circulating Tumor DNA in Oncology. Processes, 2021, 9, 2198.	1.3	0
724	Genomic evolution during locoregional recurrence in colorectal cancer determined by whole-exome sequencing. Journal of Bio-X Research, 2021, Publish Ahead of Print, .	0.3	0
725	Liquid profiling of circulating tumor DNA in colorectal cancer: steps needed to achieve its full clinical value as standard care. Molecular Oncology, 2022, 16, 2042-2056.	2.1	8
726	Utility of tumor-informed circulating tumor DNA in the clinical management of gastrointestinal malignancies. Journal of Gastrointestinal Oncology, 2021, 12, 2643-2652.	0.6	6
727	Evaluation of a 55-gene classifier as a prognostic biomarker for adjuvant chemotherapy in stage III colon cancer patients. BMC Cancer, 2021, 21, 1332.	1.1	2
729	Simultaneous monitoring of disease and microbe dynamics through plasma DNA sequencing in pediatric patients with acute lymphoblastic leukemia. Science Advances, 2022, 8, eabj1360.	4.7	2
730	Circulating Tumor DNA in Precision Oncology and Its Applications in Colorectal Cancer. International Journal of Molecular Sciences, 2022, 23, 4441.	1.8	30
731	Perioperative cell-free DNA trends predict recurrence of non-metastatic colorectal cancer significantly earlier than CEA trends over the first 2Âyears post-operatively in stage II and stage III colon cancer. International Journal of Colorectal Disease, 2022, 37, 1119-1126.	1.0	1
742	Where Are We Now and Where Might We Be Headed in Understanding and Managing Brain Metastases in Colorectal Cancer Patients?. Current Treatment Options in Oncology, 2022, 23, 980-1000.	1.3	11
743	Circulating Tumor DNA: An Emerging Tool in Gastrointestinal Cancers. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2022, 42, 279-298.	1.8	11

#	Article	IF	Citations
744	Synonymous Variants: Necessary Nuance in Our Understanding of Cancer Drivers and Treatment Outcomes. Journal of the National Cancer Institute, 2022, 114, 1072-1094.	3.0	9
745	Cell-Free Circulating (Tumor) DNA before Surgery as a Prognostic Factor in Non-Metastatic Colorectal Cancer: A Systematic Review. Cancers, 2022, 14, 2218.	1.7	16
746	Clinical Utility of Liquid Biopsy (Cell-free DNA) Based EGFR Mutation Detection Post treatment Initiation as a Disease Monitoring Tool in Patients With Advanced EGFR-mutant NSCLC. Clinical Lung Cancer, 2022, 23, 410-418.	1.1	6
747	Basic Science with Preclinical Models to Investigate and Develop Liquid Biopsy: What Are the Available Data and Is It a Fruitful Approach?. International Journal of Molecular Sciences, 2022, 23, 5343.	1.8	3
748	New Insights into Adjuvant Therapy for Localized Colon Cancer. Hematology/Oncology Clinics of North America, 2022, , .	0.9	1
749	Evolving Role of Circulating Tumor DNA and Emerging Targeted Therapy in Colorectal Cancer. Hematology/Oncology Clinics of North America, 2022, , .	0.9	0
750	Updates in the Treatment of Patients With Colorectal Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2022, 20, 1-4.	2.3	0
751	Translation of <scp>IDEA</scp> trial results into clinical practice: Analysis of the implementation of a new guideline for colon cancer. International Journal of Cancer, 2022, 151, 1270-1279.	2.3	5
752	Liquid Biopsy for Precision Adjuvant Chemotherapy in Colon Cancer. New England Journal of Medicine, 2022, 386, 2330-2331.	13.9	15
753	Utility of plasma circulating tumor DNA and tumor DNA profiles in head and neck squamous cell carcinoma. Scientific Reports, 2022, 12, .	1.6	7
754	Molecular markers in cancer. Clinica Chimica Acta, 2022, 532, 95-114.	0.5	5
755	Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer. New England Journal of Medicine, 2022, 386, 2261-2272.	13.9	337
756	The implications of cellâ€free DNAs derived from tumor viruses as biomarkers of associated cancers. Journal of Medical Virology, 2022, 94, 4677-4688.	2.5	2
757	Postoperative circulating tumor DNA combined with consensus molecular subtypes can better predict outcomes in stage III colon cancers: A prospective cohort study. European Journal of Cancer, 2022, 169, 198-209.	1.3	9
760	Biomarker Development Using Liquid Biopsy in Hepatocellular Carcinoma. Seminars in Liver Disease, 2022, 42, 188-201.	1.8	6
761	Current and Future Perspectives of Cell-Free DNA in Liquid Biopsy. Current Issues in Molecular Biology, 2022, 44, 2695-2709.	1.0	11
762	Circulating tumor DNA for diagnosis, prognosis and treatment of gastrointestinal malignancies. World Journal of Clinical Oncology, 2022, 13, 473-484.	0.9	3
763	The current state of molecular profiling in gastrointestinal malignancies. Biology Direct, 2022, 17, .	1.9	5

#	Article	IF	Citations
764	Finding Waldo: The Evolving Paradigm of Circulating Tumor DNA (ctDNA)â€"Guided Minimal Residual Disease (MRD) Assessment in Colorectal Cancer (CRC). Cancers, 2022, 14, 3078.	1.7	10
765	The Promise of Circulating Tumor DNA in Head and Neck Cancer. Cancers, 2022, 14, 2968.	1.7	11
766	Circulating tumor DNA (ctDNA) to evaluate minimal residual disease (MRD), treatment response, and posttreatment prognosis in pancreatic adenocarcinoma. Pancreatology, 2022, 22, 741-748.	0.5	8
767	Immune checkpoint inhibitors in luminal gastrointestinal malignancies: going beyond MSI-H/dMMR, TMBÂand PD-L1. Immunotherapy, 0, , .	1.0	8
768	Combining variant detection and fragment length analysis improves detection of minimal residual disease in postsurgery circulating tumour <scp>DNA</scp> of stage <scp>IIâ€"IIIA NSCLC</scp> patients. Molecular Oncology, 2022, 16, 2719-2732.	2.1	12
769	Circulating cancer biomarkers: current status and future prospects. , 2022, , 409-443.		0
770	Use of Circulating Tumour DNA to Assess Minimal Residual Disease in Gastrointestinal Cancers. Touch Reviews in Oncology & Haematology, 2022, 18, 26.	0.1	0
771	Circulating tumor DNA as a marker of minimal residual disease in nonâ€'small cell lung cancer. Malignant Tumours, 2022, 12, 14-20.	0.1	0
772	Preoperative serum ctDNA predicts early hepatocellular carcinoma recurrence and response to systemic therapies. Hepatology International, 2022, 16, 868-878.	1.9	12
775	The prognostic value of circulating in blood tumor DNA as a marker of minimal residual disease in stage Iâ€"III colorectal cancer. Uspehi Molekularnoj Onkologii, 2022, 9, 32-42.	0.1	1
776	Clinical application and prospect of MRD evaluation in lung cancer based on ctDNA level: A review. Tumori, 0, , 030089162211019.	0.6	0
777	Mind the target: circulating tumour DNA in gastrointestinal malignancies. Current Opinion in Oncology, 2022, 34, 395-402.	1.1	2
778	ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group. Annals of Oncology, 2022, 33, 750-768.	0.6	204
779	Liquid profiling for cancer patient stratification in precision medicineÂâ€" current status and challenges for successful implementation in standard care. Laboratoriums Medizin, 2022, 46, 225-236.	0.1	1
780	Prospective Study of Perioperative Circulating Tumor DNA Dynamics in Patients Undergoing Hepatectomy for Colorectal Liver Metastases. Annals of Surgery, 2023, 277, 813-820.	2.1	15
781	Using Circulating Tumor DNA in Colorectal Cancer: Current and Evolving Practices. Journal of Clinical Oncology, 2022, 40, 2846-2857.	0.8	77
782	Status of liquid profiling in precision oncologyÂâ€" the need for integrative diagnostics for successful implementation into standard care. Laboratoriums Medizin, 2022, 46, 237-245.	0.1	1
783	Detection of methylated <scp>BCAT1</scp> and <scp>IKZF1</scp> after curativeâ€intent treatment as a prognostic indicator for colorectal cancer recurrence. Cancer Medicine, 2023, 12, 1319-1329.	1.3	5

#	Article	IF	Citations
784	Combination of CDX2 H-score quantitative analysis with CD3 AI-guided analysis identifies patients with a good prognosis only in stage III colon cancer. European Journal of Cancer, 2022, 172, 221-230.	1.3	5
785	Personalized Cancer Care. , 2023, , 83-90.		0
786	Targeted Therapy in Early Stage Non-small Cell Lung Cancer. Current Treatment Options in Oncology, 2022, 23, 1169-1184.	1.3	4
787	Serial Analysis of Gene Mutations and Gene Expression during First-Line Chemotherapy against Metastatic Colorectal Cancer: Identification of Potentially Actionable Targets within the Multicenter Prospective Biomarker Study REVEAL. Cancers, 2022, 14, 3631.	1.7	3
788	Clinical Validity of Tumor-Informed Circulating Tumor DNA Analysis in Patients Undergoing Surgery of Colorectal Metastases. Diseases of the Colon and Rectum, 0, Publish Ahead of Print, .	0.7	1
789	Prognostic potential of circulating tumor DNA detection at different time periods in resectable non-small cell lung cancer: Evidence from a meta-analysis. Critical Reviews in Oncology/Hematology, 2022, 177, 103771.	2.0	5
790	Comparing singleâ€target and multitarget approaches for postoperative circulating tumour <scp>DNA</scp> detection in stage <scp>IIâ€“III</scp> colorectal cancer patients. Molecular Oncology, 2022, 16, 3654-3665.	2.1	7
791	Emerging Technologies for the Detection of Cancer Micrometastasis. Technology in Cancer Research and Treatment, 2022, 21, 153303382211003.	0.8	5
792	Targeted Mutational Analysis of Circulating Tumor DNA to Decipher Temporal Heterogeneity of High-Grade Serous Ovarian Cancer. Cancers, 2022, 14, 3697.	1.7	3
793	Diagnostic and prognostic biomarkers in colorectal cancer and the potential role of exosomes in drug delivery. Cellular Signalling, 2022, 99, 110413.	1.7	7
794	Circulation tumour <scp>DNA</scp> in predicting recurrence and prognosis in operable colorectal cancer patients: A metaâ€analysis. European Journal of Clinical Investigation, 2022, 52, .	1.7	4
795	Circulating DNA in the neoadjuvant setting of early stage colon cancer. Acta OncolÃ³gica, 2022, 61, 1223-1229.	0.8	4
796	Predictive Value of Circulating Tumor Cells Based on Subtraction Enrichment for Recurrence Risk in Stage II Colorectal Cancer. ACS Applied Materials & Interfaces, 2022, 14, 35389-35399.	4.0	1
797	SAMHD1 as a prognostic and predictive biomarker in stage II colorectal cancer: A multicenter cohort study. Frontiers in Oncology, 0, 12, .	1.3	1
798	Bintrafusp Alfa, an Anti-PD-L1:TGFÎ² Trap Fusion Protein, in Patients with ctDNA-positive, Liver-limited Metastatic Colorectal Cancer. Cancer Research Communications, 2022, 2, 979-986.	0.7	9
799	Tailoring adjuvant chemotherapy by circulating tumor DNA (ctDNA) in older patients with stage II-III colon cancer. Journal of Geriatric Oncology, 2023, 14, 101367.	0.5	0
802	Bioplatforms in liquid biopsy: advances in the techniques for isolation, characterization and clinical applications. Biotechnology and Genetic Engineering Reviews, 2022, 38, 339-383.	2.4	8
803	Circulating Tumor DNA as a Biomarker for Monitoring Patients with Solid Cancers: Comparison with Standard Protein Biomarkers. Clinical Chemistry, 2022, 68, 1381-1390.	1.5	17

#	Article	IF	Citations
804	Serial Circulating Tumor DNA in Monitoring the Effect of Neoadjuvant and Adjuvant Immunotherapy in Patients With Colon Cancer: Case Series and Review of the Literature. Journal of Immunotherapy, 2022, 45, 358-362.	1.2	5
805	Introduction of Nanomaterials to Biosensors for Exosome Detection: Case Study for Cancer Analysis. Biosensors, 2022, 12, 648.	2.3	7
806	Roles of circulating tumor DNA in PD-1/PD-L1 immune checkpoint Inhibitors: Current evidence and future directions. International Immunopharmacology, 2022, 111, 109173.	1.7	3
807	HPV and head and neck cancers: Towards early diagnosis and prevention. Tumour Virus Research, 2022, 14, 200245.	1.5	15
808	Circulating tumor DNA-minimal residual disease: An up-and-coming nova in resectable non-small-cell lung cancer. Critical Reviews in Oncology/Hematology, 2022, 179, 103800.	2.0	4
809	Assessment of Tumour Response to Neoadjuvant Therapy for the Treatment of Oesophageal Cancer. GI Surgery Annual, 2022, , 147-162.	0.0	0
810	Biotechnology for diagnosis, prognosis, and monitoring cancer. , 2022, , 49-69.		0
811	Early detection of colorectal cancer somatic mutations using cfDNA liquid biopsies in a murine carcinogenesis model. Journal of Cancer, 2022, 13, 3404-3414.	1.2	2
812	Leveraging Comprehensive Cancer Registry Data to Enable a Broad Range of Research, Audit and Patient Support Activities. Cancers, 2022, 14, 4131.	1.7	8
813	UMIErrorCorrect and UMIAnalyzer: Software for Consensus Read Generation, Error Correction, and Visualization Using Unique Molecular Identifiers. Clinical Chemistry, 2022, 68, 1425-1435.	1.5	3
814	Accurate measurement of microsatellite length by disrupting its tandem repeat structure. Nucleic Acids Research, 2022, 50, e116-e116.	6.5	4
815	Liquid Biopsy Analysis as a Tool for TKI-Based Treatment in Non-Small Cell Lung Cancer. Cells, 2022, 11, 2871.	1.8	6
816	ctDNA-guided adjuvant chemotherapy for colorectal cancerâ€”ready for prime time?. Cancer Cell, 2022, 40, 911-913.	7.7	1
817	Clinical applications of circulating tumor-derived DNA in the management of gastrointestinal cancers â€“ current evidence and future directions. Frontiers in Oncology, 0, 12, .	1.3	2
818	Circulating Tumor DNA-Based Disease Monitoring of Patients with Locally Advanced Esophageal Cancer. Cancers, 2022, 14, 4417.	1.7	7
819	A Methylation-Based Prognostic Signature in Stage II Colorectal Patients: Considerations for Clinical Adoption. Journal of the National Cancer Institute, 0, , .	3.0	0
822	Predictive value of early kinetics of <scp>ctDNA</scp> combined with <scp>cfDNA</scp> and serum <scp>CEA</scp> for <scp>EGFRâ€TKI</scp> treatment in advanced nonâ€small cell lung cancer. Thoracic Cancer, 0, , .	0.8	4
823	Management of Resectable and Borderline Resectable Disease: Medical Oncology. , 2022, , 139-151.		0

#	Article	IF	Citations
824	Circulating DNA in patients undergoing loco-regional treatment of colorectal cancer metastases: a systematic review and meta-analysis. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592211331.	1.4	7
825	Case report: Patient specific combination of surgery and immunotherapy in advanced squamous cell carcinoma of the head and neck â€“ a case series and review of literature. Frontiers in Immunology, 0, 13, .	2.2	4
826	Cell-Free DNA as a Prognostic Biomarker for Monitoring Muscle-Invasive Bladder Cancer. International Journal of Molecular Sciences, 2022, 23, 11732.	1.8	6
827	Overview of predictive and prognostic biomarkers and their importance in developing a clinical pharmacology treatment plan in colorectal cancer patients. Expert Review of Clinical Pharmacology, 0, , 1-10.	1.3	0
828	The current status of cellâ€free human papillomavirus <scp>DNA</scp> as a biomarker in cervical cancer and other <scp>HPV</scp>â€associated tumors: A review. International Journal of Cancer, 2023, 152, 2232-2242.	2.3	4
829	ASCO 2022 update: (neo-)adjuvant treatment of colorectal cancer. Memo - Magazine of European Medical Oncology, 0, , .	0.3	0
830	Complex RNA world in small extracellular vesicles for liquid biopsy in cancer management. , 2022, 1, 100015.		4
831	Tumour break load is a biologically relevant feature of genomic instability with prognostic value in colorectal cancer. European Journal of Cancer, 2022, 177, 94-102.	1.3	2
832	Ready for ctDNA-guided treatment decisions in colorectal cancer?. Journal of the National Cancer Center, 2023, 3, 1-3.	3.0	1
833	Postoperative circulating tumor DNA detection is associated with the risk of recurrence in patients resected for a stage II colorectal cancer. Frontiers in Oncology, 0, 12, .	1.3	1
834	A Micro-Costing Framework for Circulating Tumor DNA Testing in Dutch Clinical Practice. Journal of Molecular Diagnostics, 2023, 25, 36-45.	1.2	7
835	Tapping into the genome: the role of CSF ctDNA liquid biopsy in glioma. Neuro-Oncology Advances, 2022, 4, ii33-ii40.	0.4	1
836	Circulating Tumor DNA as a Marker of Minimal Residual Disease After Radical Resection of Colorectal Liver Metastases. JCO Precision Oncology, 2022, , .	1.5	9
837	The utility of ctDNA in detecting minimal residual disease following curative surgery in colorectal cancer: a systematic review and meta-analysis. British Journal of Cancer, 2023, 128, 297-309.	2.9	16
838	Circulating tumor DNA in early-stage colon cancer: ready for prime time or needing refinement?. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592211439.	1.4	3
840	Adjuvant Systemic Chemotherapy. , 2022, , 301-308.		0
841	A bibliometric and scientometric: analysis towards global pattern and trends related to aerosol and precipitation studies from 2002 to 2022. Air Quality, Atmosphere and Health, 2023, 16, 613-628.	1.5	7
842	Biomarkers in the development of individualized treatment regimens for colorectal cancer. Frontiers in Medicine, 0, 9, .	1.2	3

#	Article	IF	Citations
843	How ctDNA Changing the Landscape of Management of Colorectal Cancers. , 0, 1, 33-40.		0
845	Peritoneal recurrence after resection for Stage Iâ€“III colorectal cancer: A population analysis. Journal of Surgical Oncology, 2023, 127, 678-687.	0.8	2
846	The Role of Cell-Free DNA in Cancer Treatment Decision Making. Cancers, 2022, 14, 6115.	1.7	10
847	Genetic features and therapeutic relevance of emergent circulating tumor DNA alterations in refractory non-colorectal gastrointestinal cancers. Nature Communications, 2022, 13, .	5.8	2
848	Molecular Residual Disease-guided Adjuvant Treatment in Resected Colorectal Cancer: Focus on CIRCULATE-Japan. Clinical Colorectal Cancer, 2023, 22, 53-58.	1.0	3
849	Realâ€world adjuvant chemotherapy treatment patterns and outcomes over time for resected stage II and III colorectal cancer. Asia-Pacific Journal of Clinical Oncology, 0, , .	0.7	0
851	Post-operative ctDNA monitoring in stage I colon cancer: A case report. Frontiers in Oncology, 0, 12, .	1.3	1
852	Circulating Tumor DNA: Towards More Individualized Treatment for Patients with Resectable Colorectal Cancer. Journal of Gastrointestinal Cancer, 2023, 54, 1071-1081.	0.6	2
854	Copy Number Variations as Determinants of Colorectal Tumor Progression in Liquid Biopsies. International Journal of Molecular Sciences, 2023, 24, 1738.	1.8	2
855	Shaping the Future of Immunotherapy Targets and Biomarkers in Melanoma and Non-Melanoma Cutaneous Cancers. International Journal of Molecular Sciences, 2023, 24, 1294.	1.8	6
856	Multifunctional Hybrid Nanozymes for Magnetic Enrichment and Bioelectrocatalytic Sensing of Circulating Tumor RNA during Minimal Residual Disease Monitoring. Catalysts, 2023, 13, 178.	1.6	1
857	Prognostic and predictive value of Immunoscore and its correlation with ctDNA in stage II colorectal cancer. OncoImmunology, 2023, 12, .	2.1	7
858	Circulating tumor DNA-guided minimal residual disease assessment in colorectal cancer. Pharmacogenomics, 2023, 24, 1-4.	0.6	0
859	The methylome and cell-free DNA: current applications in medicine and pediatric disease. Pediatric Research, 2023, 94, 89-95.	1.1	2
860	Essential updates 2020/2021: Advancing precision medicine for comprehensive rectal cancer treatment. Annals of Gastroenterological Surgery, 2023, 7, 198-215.	1.2	5
861	Recurrence risk assessment for stage III colorectal cancer based on five methylation biomarkers in plasma cellâ€free DNA. Journal of Pathology, 0, , .	2.1	1
862	The T-CEA score: a useful prognostic indicator based on postoperative CEA and pathological T4 levels for patients with stage IIâ€“III colorectal cancer. Surgery Today, 0, , .	0.7	1
863	Current clinically validated applications of liquid biopsy. , 2023, , 63-81.		0

#	Article	IF	Citations
864	Loss of Heterozygosity in the Circulating Tumor DNA and CD138+ Bone Marrow Cells in Multiple Myeloma. Genes, 2023, 14, 351.	1.0	1
865	Tumor-informed or tumor-agnostic circulating tumor DNA as a biomarker for risk of recurrence in resected colorectal cancer patients. Frontiers in Oncology, 0, 12, .	1.3	11
866	Circulating Tumour DNA: A Promising Cancer Biomarker. , 2023, , 100-114.		0
867	Genetics, Genomics and Emerging Molecular Therapies of Pancreatic Cancer. Cancers, 2023, 15, 779.	1.7	4
868	Circulating tumor DNA detection after neoadjuvant treatment and surgery predicts recurrence in patients with early-stage and locally advanced rectal cancer. European Journal of Surgical Oncology, 2023, 49, 1283-1290.	0.5	2
869	Development and validation of postoperative circulating tumor DNA combined with clinicopathological risk factors for recurrence prediction in patients with stage I-III colorectal cancer. Journal of Translational Medicine, 2023, 21, .	1.8	1
870	ctDNA to Guide Treatment of Colorectal Cancer: Ready for Standard of Care?. Current Treatment Options in Oncology, 2023, 24, 76-92.	1.3	4
871	Health economic evidence for adjuvant chemotherapy in stage II and III colon cancer: a systematic review. Cost Effectiveness and Resource Allocation, 2023, 21, .	0.6	0
872	Postoperative circulating tumor <scp>DNA</scp> can refine risk stratification in resectable lung cancer: results from a multicenter study. Molecular Oncology, 2023, 17, 825-838.	2.1	0
873	Why the length of recurrence-free survival or â€˜lead-timesâ€™ can be misleading. Comment on: Callesen LB, Takacova T, Hamfjord J, et al. Circulating DNA in patients undergoing loco-regional treatment of colorectal cancer metastases: a systematic review and meta-analysis. Therapeutic Advances in Medical Oncology, 2023, 15, 175883592311563.	1.4	0
874	Clearance Profile of Circulating Tumor Human Papillomavirus DNA During Radiotherapy Predicts Clinical Outcomes in Human Papillomavirusâ€“Related Oropharyngeal Cancer. JCO Precision Oncology, 2023, , .	1.5	1
875	Paired Comparison of Routine Molecular Screening of Patient Samples with Advanced Non-Small Cell Lung Cancer in Circulating Cell-Free DNA Using Three Targeted Assays. Cancers, 2023, 15, 1574.	1.7	0
876	Minimal Residual Disease in Colorectal Cancer: Are We Finding the Needle in a Haystack?. Cells, 2023, 12, 1068.	1.8	1
877	Noninvasive genomic profiling of somatic mutations in oral cavity cancers. Oral Oncology, 2023, 140, 106372.	0.8	1
878	Overview of Affordable Upfront Point-of-Care Testing for Cancer Detection. , 2022, , 137-154.		0
879	Opportunities on the horizon for the management of early colon cancer. Critical Reviews in Oncology/Hematology, 2023, 183, 103918.	2.0	2
880	Clinical application of liquid biopsy in endometrial carcinoma. , 2023, 40, .		1
881	CtDNAâ€™s prognostic value in patients with early-stage colorectal cancer after surgery: A meta-analysis and systematic review. Medicine (United States), 2023, 102, e32939.	0.4	2

#	Article	IF	Citations
882	Regulatory implications of ctDNA in immuno-oncology for solid tumors. , 2023, 11, e005344.		10
883	The Position of Circulating Tumor DNA in the Clinical Management of Colorectal Cancer. Cancers, 2023, 15, 1284.	1.7	5
884	Longitudinal ctDNA profiling in precision oncology and immunÎ¿-oncology. Drug Discovery Today, 2023, 28, 103540.	3.2	3
885	A DNA methylation signature for the prediction of tumour recurrence in stage II colorectal cancer. British Journal of Cancer, 2023, 128, 1681-1689.	2.9	6
886	Circulating Tumor DNA: The Dawn of a New Era in the Optimization of Chemotherapeutic Strategies for Metastatic Colo-Rectal Cancer Focusing on RAS Mutation. Cancers, 2023, 15, 1473.	1.7	1
887	Diagnostic value of liquid biopsy in the era of precision medicine: 10 years of clinical evidence in cancer. Exploration of Targeted Anti-tumor Therapy, 0, , 102-138.	0.5	14
888	Early Plasma Circulating Tumor DNA as a Potential Biomarker of Disease Recurrence in Non-metastatic Prostate Cancer. Cancer Research and Treatment, 2023, 55, 969-977.	1.3	1
889	Significance of Distinct Liquid Biopsy Compartments in Evaluating Somatic Mutations for Targeted Therapy Selection in Cancer of Unknown Primary. Journal of Gastrointestinal Cancer, 2023, 54, 1276-1285.	0.6	0
890	Liquid Biopsies, Novel Approaches and Future Directions. Cancers, 2023, 15, 1579.	1.7	18
891	Liver transplantation in metastatic colorectal cancer: are we ready for it?. British Journal of Cancer, 2023, 128, 1797-1806.	2.9	5
892	Plasma-only circulating tumor DNA analysis detects minimal residual disease and predicts early relapse in hepatocellular carcinoma patients undergoing curative resection. Frontiers in Oncology, 0, 13, .	1.3	0
893	Circulating tumour DNA in the evolving treatment landscape of locally advanced rectal cancer: where does it fit in?. Therapeutic Advances in Medical Oncology, 2023, 15, 175883592311601.	1.4	2
894	Utilizing Plasma Circulating Tumor DNA Sequencing for Precision Medicine in the Management of Solid Cancers. Cancer Research and Treatment, 2023, 55, 367-384.	1.3	1
895	Locally performed postoperative circulating tumour <scp>DNA</scp> testing performed during routine clinical care to predict recurrence of colorectal cancer. ANZ Journal of Surgery, 2023, 93, 2473-2480.	0.3	1
896	Time for a lead-time definition? Author response to â€˜Why the length of recurrence free survival or â€œlead-timesâ€• can be misleading. Comment on: Callesen LB, Takacova T, Hamfjord J, et al. Circulating DNA in patients undergoing loco-regional treatment of colorectal cancer metastases: a systematic review and meta-analysisâ€™. Therapeutic Advances in Medical Oncology, 2023, 15, 175883592311563.	1.4	1
897	ctDNA guided adjuvant chemotherapy versus standard of care adjuvant chemotherapy after curative surgery in patients with high risk stage II or stage III colorectal cancer: a multi-centre, prospective, randomised control trial (TRACC Part C). BMC Cancer, 2023, 23, .	1.1	5
898	Is frequent measurement of tumor markers beneficial for postoperative surveillance of colorectal cancer?. International Journal of Colorectal Disease, 2023, 38, .	1.0	0
899	Circulating tumor DNA in molecular assessment feasibly predicts early progression of pancreatic cancer that cannot be identified via initial imaging. Scientific Reports, 2023, 13, .	1.6	3

#	Article	IF	Citations
900	Current Applications of Liquid Biopsy in Gastrointestinal Cancer Diseaseâ€"From Early Cancer Detection to Individualized Cancer Treatment. Cancers, 2023, 15, 1924.	1.7	1
901	Enhancing clinical potential of liquid biopsy through a multi-omic approach: A systematic review. Frontiers in Genetics, 0, 14, .	1.1	11
902	Epigenetic liquid biopsies for minimal residual disease, whatâ€™s around the corner?. Frontiers in Oncology, 0, 13, .	1.3	3
903	Investigate the application of postoperative ctDNA-based molecular residual disease detection in monitoring tumor recurrence in patients with non-small cell lung cancerâ€"â€"A retrospective study of ctDNA. Frontiers in Oncology, 0, 13, .	1.3	1
904	Minimal Residual Disease Monitoring in Radically Treated Non-Small Cell Lung Cancer: Challenges and Future Directions. OncoTargets and Therapy, 0, Volume 16, 249-259.	1.0	2
905	Detecting liquid remnants of solid tumors treated with curative intent: Circulating tumor DNA as a biomarker of minimal residual disease (Review). Oncology Reports, 2023, 49, .	1.2	4
906	Early Detection of Molecular Residual Disease and Risk Stratification for Stage I to III Colorectal Cancer via Circulating Tumor DNA Methylation. JAMA Oncology, 2023, 9, 770.	3.4	15
923	Lessons learned in adjuvant colorectal cancer. Memo - Magazine of European Medical Oncology, 2023, 16, 113-115.	0.3	1
933	Zukunftspotenziale der Labormedizin. , 2023, , 181-231.		0
934	Case Report: A rare synchronous multiple gastric carcinoma achieved progression-free disease through NGS-guided serial treatment. Frontiers in Oncology, 0, 13, .	1.3	0
935	Role of Circulating Tumor DNA Among Patients with Colorectal Peritoneal Metastases. Journal of Gastrointestinal Cancer, 0, , .	0.6	1
936	Diagnosis, Monitoring, and Prognosis of Liquid Biopsy in Cancer Immunotherapy. Methods in Molecular Biology, 2023, , 127-143.	0.4	0
937	The Implication of Liquid Biopsy in the Non-small Cell Lung Cancer: Potential and Expectation. Methods in Molecular Biology, 2023, , 145-163.	0.4	1
938	Role of Circulating Tumor DNA in Colorectal Cancer. Methods in Molecular Biology, 2023, , 227-236.	0.4	0
947	Redefining precision radiotherapy through liquid biopsy. British Journal of Cancer, 2023, 129, 900-903.	2.9	4
964	Minor Allele Enrichment in Liquid Biopsies Using Nuclease-Assisted Elimination of Wild-Type DNA. Current Cancer Research, 2023, , 27-42.	0.2	0
967	Re: Molecular testing to deliver personalised chemotherapy recommendations. BMC Medicine, 2023, 21, .	2.3	1
969	Minimal residual disease in solid tumors: an overview. Frontiers of Medicine, 2023, 17, 649-674.	1.5	0

#	Article	IF	Citations
981	Personalizing adjuvant therapy for patients with colorectal cancer. Nature Reviews Clinical Oncology, 2024, 21, 67-79.	12.5	1
987	Liquid Biopsies for Pancreatic Cancer: Is It Ready for Prime Time?. , 2023, , 147-157.		0
1022	Protein prognostic biomarkers in stage II colorectal cancer: implications for post-operative management. , 2024, 2, .		0